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ABSTRACT 
The MondoA/TXNIP axis controls glucose homeostasis. The transcription factor 
MondoA senses glucose-6-phosphate (G6P) and responds by driving expression of 
thioredoxin-interacting protein (TXNIP), a negative regulator of glucose uptake. The 
transcriptional activity of MondoA requires oxidative phosphorylation, yet the 
mechanism is unknown. We studied nutrient sensing by MondoA in the context of 
acidosis treatment and protein synthesis inhibition, both of which drive MondoA 
transcriptional activity and TXNIP expression. Both acidosis and protein synthesis 
inhibition converge on increased synthesis of mitochondrial-ATP (mtATP). Intracellular 
acidification leads to mitochondrial hyperpolarization and mtATP production through the 
ATP synthase. Protein synthesis inhibitors also drive mtATP production, likely through 
increased TCA cycle flux. As mtATP is exported from the mitochondria, it is consumed 
by mitochondria-bound hexokinase in a reaction that produces G6P. The localized 
production of G6P drives MondoA transcriptional activity. Thus, by simultaneously 
sensing glucose and mtATP via production of G6P, MondoA acts as a coincidence 
detector of the cells primary energy sources. We further show that MondoA drives an 
adaptive transcriptional response to intracellular acidification and protein synthesis 
inhibition, of which increased TXNIP is a predominant feature. By characterizing the 
transcriptional consequences of MondoA and TXNIP loss, we show that TXNIP supports 
MondoA-dependent transcription. Because TXNIP loss causes a shift away from 
iv 
oxidative metabolism toward aerobic glycolysis, we propose that loss of TXNIP leads to 
decreased mtATP production, thus restricting MondoA transcriptional activity. Finally, 
MondoA loss sensitizes cells to Myc-driven cell death. Together these findings further 
our knowledge of 1) metabolic rewiring during acidosis treatment and protein synthesis 
inhibition, 2) mtATP and glucose sensing by MondoA, and 3) the biological impacts of 
MondoA transcriptional activity. Thus, we propose that the MondoA/TXNIP axis is a 
fundamental attribute of central carbon metabolism and homeostasis. 
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1.1. Metabolic rewiring in cancer 
 In the early 1900s, Otto Warburg made the seminal observation that cancer cells 
preferentially metabolize glucose in glycolysis and lactic fermentation, which is different 
from nontransformed cells that primarily use oxidative phosphorylation (Koppenol et al., 
2011; Otto, 2016; Vander Heiden et al., 2009; Warburg, 1956). Dysregulation of glucose 
metabolism is now a widely recognized hallmark of cancer and is necessary to support 
the bioenergetic, biosynthetic and redox demands of cancer cells (DeBerardinis and 
Chandel, 2016; Hanahan and Weinberg, 2011; Pavlova and Thompson, 2016). Defining 
the metabolic alterations in cancer has had a broad impact on the detection and treatment 
of cancer; yet there is still much to learn about nutrient acquisition and utilization in 
cancer. 
 
1.1.1. Glycolysis and pH regulation 
 Among Warburg’s important findings is that cancer cells have elevated glucose 
uptake relative to surrounding tissues (Hay, 2016; Vander Heiden et al., 2009; Ward and 
Thompson, 2012). This observation is the key principle behind 18F-deoxyglucose positron 
emission tomography (FDG-PET), which is routinely used to visualize human tumors in 
situ. FDG is a glucose analogue and its uptake is controlled by the same mechanisms that 
control glucose uptake. Accumulation of FDG in tumors is used to assess tumor size and 
metabolic state. Decreased glucose uptake as measured by FDG-PET is a significant 
positive prognostic factor (Vander Heiden et al., 2009). Given that increased glucose 
uptake is a characteristic feature of tumors, substantial work has gone into targeting 
glucose uptake and metabolism in cancer. There is growing evidence that targeting 
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glucose uptake directly may lead to selective targeting and eradication of cancer cells 
(Hay, 2016). 
 By preferentially converting pyruvate into lactate, cancer cells produce NAD+, 
which supports glycolytic flux by serving as a cofactor for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH; Figure 1.1; (Pavlova and Thompson, 2016; Vander Heiden et 
al., 2009). Lactate secretion out of the cell enforces the forward progression of glycolysis 
and lactic fermentation (Hay, 2016). Lactate secretion is facilitated by monocarboxylate 
transporters (MCTs), which transport one lactate molecule and one proton to the 
extracellular space (Figure 1.1). MCTs are upregulated in a number of cancers (Webb et 
al., 2011). Lactate secretion prevents the accumulation of lactate, which can inhibit the 
rate limiting glycolytic enzyme phosphofructokinase-1 (PFK1) (Webb et al., 2011).  
Thus, enhanced lactate production by glycolysis and its export, along with protons, to the 
extracellular space are key features of metabolic reprogramming towards aerobic 
glycolysis in cancer. Chapter 2 outlines a mechanism by which intracellular acidification 
triggers the MondoA/TXNIP axis to control glucose metabolism and pH homeostasis. 
 MCT-driven export of lactate and protons to the extracellular space leads to 
intracellular alkalization, a hallmark of cancer metabolism. Increased expression and 
activity of Na+-H+ exchanger 1 (NHE1), carbonic anhydrases and V-ATPases also 
contribute to intracellular alkalization (Webb et al., 2011). Thus, normal cells have lower 
intracellular than extracellular pH, and cancer cells have a higher intracellular than 
extracellular pH. This pH gradient reversal affords cancer cells numerous autonomous 
and nonautonomous advantages. First, intracellular alkalization increases PFK1 activity 
about 100-fold, thus increasing glycolysis (Andres et al., 1990; Frieden et al., 1976; 
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Trivedi and Danforth, 1966). Second, intracellular alkalization drives proliferative signals 
and restricts cell death signals (Lagadic-Gossmann et al., 2004; Matsuyama et al., 2000; 
Pouyssegur et al., 1985). Third, acidic extracellular space supports matrix remodeling and 
cell invasion (Stock and Schwab, 2009). Fourth, the reversal of the pH gradient prevents 
the cellular retention and efficacy of various chemotherapies (Webb et al., 2011). Fifth, 
extracellular acidification allows cancer cells to evade death signals from the immune 
system (Fischer et al., 2007; Webb et al., 2011). Given its predominant role in metabolic 
rewiring and cancer progression, altered pH might be exploited for cancer-specific 
therapeutics. In Chapter 2, we show that the MondoA/TXNIP axis is an integral feature 
of the adaptive response to intracellular acidification. 
 In addition to acidosis, cancer cells adapt to a milieu of environmental stresses 
such as hypoxia, acidosis, and attacks by the immune system (Pavlova and Thompson, 
2016). Metabolic alterations allow for survival and proliferation in such harsh conditions. 
Additionally, these stresses are co-opted by cancer as selective pressure for clones that 
are most resistant to apoptosis (Sloan and Ayer, 2010). 
 
1.1.2. Bioenergetics and biosynthesis 
 Complementing its role in ATP production, glucose is also an important substrate 
for the generation of biomass. The first committed step in glucose metabolism is the 
generation of glucose-6-phosphate (G6P), which is a branching point for numerous 
biosynthetic pathways. G6P is used in the pentose-phosphate pathway as a major source 
of NADPH and ribonucleotides (Patra and Hay, 2014). G6P is also used in the 
hexosamine synthesis pathway, which provides substrates for the glycosylation of 
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proteins, and in glycogensis, which has a role metabolic reprogramming (Zois and Harris, 
2016). Glycerol-3-phosphate is used in fatty-acid synthesis (Hay, 2016). Finally, 3-
phosphoglycerate is used to fuel serine and glycine biosynthesis, which generates 
substrates for one-carbon metabolism and nucleotide production (Yang and Vousden, 
2016). Thus glucose-derived glycolytic intermediates serve as precursors for biosynthetic 
reactions (Figure 1.1). 
 While cancer cells preferentially convert pyruvate into lactate, a small amount of 
pyruvate enters the mitochondria where it is metabolized in the TCA cycle (Vander 
Heiden et al., 2009). Early reports by Warburg and others suggested that mitochondria 
are nonfunctional in cancer; however, it is now clear that mitochondrial metabolism plays 
an essential role in cancer progression (King and Attardi, 1989; Koppenol et al., 2011; 
Sullivan et al., 2015). Pyruvate and glutamine anaplerosis are increased as a source of 
carbons for the TCA cycle (Altman et al., 2016). Further, Myc and other oncogenes 
stimulate mitochondrial biogenesis, demonstrating an essential role for the mitochondria 
in oncogenesis (Dang, 2013; Li et al., 2005). Finally, growing evidence indicates that the 
electron transport chain (ETC) is essential for redox homeostasis and cancer cell survival 
(Birsoy et al., 2015; Sullivan et al., 2015). 
 In a limited number of patients, targeting cancer metabolism has shown great 
promise. In 1948 Sidney Farber showed that aminopterin, a folate antagonist, and later 
amethopterin (now methotrexate), induced remission in children with acute lymphocytic 
leukemia (ALL; (Farber and Diamond, 1948). This was the first successful demonstration 
of chemotherapy in the clinic (Goodsell, 1999; Rajagopalan et al., 2002; Wright et al., 
1951). Mechanistically, methotrexate inhibits dihydrofolate reductase, an important 
6 
 
enzyme in nucleotide biosynthesis. A few years later, Charles Heidelberger demonstrated 
tumor regression in patients treated with 5-fluorouracil (5-FU; (Heidelberger et al., 1957), 
which is an inhibitor of thymidylate synthase and nucleotide biosynthesis. 5-FU and 
methotrexate are the first examples of targeting cancer metabolism. Both therapies are 
incredibly virulent to cancer and are thus still used in the clinic today; however, 
widespread toxicity is a major challenge. The new frontier in chemotherapy is to leverage 
our mechanistic knowledge of cancer to be more specific in the cells and metabolic 
pathways we target (Luengo et al., 2017). Understanding the full complement of 
metabolic liabilities in cancer will help to identify other metabolic targets and therapies 
for cancer patients. 
 
1.2. MondoA and glucose homeostasis 
 MondoA is the sentinel regulator of glucose-induced transcription, and it controls 
gene expression circuits that determine cellular fuel choice (Stoltzman et al., 2011; 
Stoltzman et al., 2008; our unpublished data). Dysregulation of MondoA underlies 
metabolic reprogramming in diabetes and cancer (O'Shea and Ayer, 2013; Richards et al., 
2017a; Richards et al., 2017b). Given its role in metabolic homeostasis, we and others 
have proposed that the MondoA/TXNIP axis might be a therapeutic target for cancer. 
 
1.2.1 Structure and function 
 MondoA is a member of the basic helix-loop-helix leucine zipper (bHLH-Zip) 
family of transcription factors. MondoA requires heterodimerization with Mlx, another 
bHLH-Zip transcription factor, for DNA-binding and transcriptional activity (Billin et al., 
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2000). MondoA:Mlx works within a broader network of bHLH-Zip transcription factors 
that regulates nutrient utilization and sensing, the Myc-superfamily of transcription 
factors (Figure 1.2A). ChREBP, or MondoB, is a paralogue of MondoA that also binds 
Mlx. Both MondoA:Mlx and ChREBP:Mlx sense the metabolic status of the cell and 
respond by driving expression of genes that control nutrient availability and utilization 
(O'Shea and Ayer, 2013). Mlx can also dimerize with the transcriptional repressors 
Mxd1, Mxd4, Mnt or Mga. These heterocomplexes repress genes involved in growth and 
self-renewal. Mxd1, Mxd4, Mnt, Mga, Mxi1 and Mxd3 can interact with Max to drive 
the same phenotypes. Finally, Max can interact with c-Myc, N-Myc or L-Myc 
(collectively Myc). Myc:Max is a master regulator of cell growth, proliferation and 
motility (Diolaiti et al., 2015; Zhou and Hurlin, 2001). Myc-superfamily heterodimers all 
bind CANNTG E-boxes. We and others have described transcriptional antagonism 
between members of the Myc-superfamily (Carroll and Diolaiti, 2016; Carroll et al., 
2015; Diolaiti et al., 2015; Wilde and Ayer, 2015; Yang and Hurlin, 2017), yet further 
work will be required to elucidate how transcription is coordinated by all members of the 
Myc-superfamily. The simple model that has emerged is that the Myc-superfamily 
coordinates nutrient utilization and availability. 
 MondoA and Mlx interact with each other and bind DNA through their bHLH-Zip 
domains. MondoA:Mlx heterodimers bind carbohydrate-responsive elements (ChoRE), 
which are two E-boxes separated by five nucleotides. A C-terminal region of both 
MondoA and Mlx, which we dubbed the dimerization and cytoplasmic localization 
domain (DCD), is also necessary for MondoA:Mlx interaction and nuclear localization 
(Figure 1.2B; (Eilers et al., 2002; Peterson et al., 2010). Further, MondoA contains a 
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strong transactivation domain and five Mondo-conserved domains (MCRs) at the N-
terminus (Billin and Ayer, 2006; Billin et al., 2000). The MCRs are highly conserved in 
MondoA orthologues and control nutrient sensing (McFerrin and Atchley, 2012). An N-
terminal region that spans MCRs I-IV has been reported as a low-glucose inhibitory 
domain (LID) and is involved in repressing transcriptional activation under low glucose 
conditions (Peterson et al., 2010). A glucose responsive activation element (GRACE), 
which includes MCRV, is responsible for glucose sensing and glucose-induced 
transcription (McFerrin and Atchley, 2012). Mechanistically, we showed that MCRII and 
MCRIII coordinate the glucose-induced nucleocytoplasmic shuttling of MondoA (Eilers 
et al., 2002). The roles of MCRs I, IV and V have not been well characterized. 
 Unlike other members of the Myc-superfamily, MondoA is not constitutively 
nuclear. Rather, it shuttles between the outer-mitochondrial membrane (OMM) and the 
nucleus (Eilers et al., 2002; Peterson et al., 2010; Sans et al., 2006). We have previously 
demonstrated that MCRIII interacts with 14-3-3 family members, a class of proteins that 
bind phosphorylated residues (Figure 1.3A; (Eilers et al., 2002; Morrison, 2009; Peterson 
et al., 2010). ChREBP also binds 14-3-3, and crystal structures of ChREBP/14-3-3 
indicate that the interaction occurs independent of phosphorylated residues in ChREBP: a 
novel mode of 14-3-3 binding (Ge et al., 2012; Sato et al., 2016). Rather a sulfate ion 
coordinates the binding. Consistent with this finding, the MondoA/14-3-3 interaction is 
independent of phosphorylatable residues (Peterson et al., 2010). Functionally, we 
observed that 14-3-3 binding is necessary for nuclear retention of MondoA (Eilers et al., 
2002). Our working model is that 14-3-3 binding to MondoA occludes Crm1 binding at a 
canonical nuclear-export signal in MCRII (Figure 1.3B). Given the overlapping role for 
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G6P and 14-3-3 in MondoA activity, we postulated that the MondoA/14-3-3 interaction 
is coordinated by G6P. Using the published structure of ChREBP and 14-3-3, we 
conducted molecular modeling to demonstrate that G6P rather than a sulfate ion could 
coordinate the interaction. G6P fits within steric and electrostatic constraints of the 
binding interface (Figure 1.3C), leading us to hypothesize that G6P coordinates the 
interaction between MondoA and 14-3-3, thus leading to a blockage of Crm1 binding to 
MCRII and the subsequent nuclear retention and transcriptional activity of MondoA. 
 
1.2.2. Nutrient sensing by MondoA 
 A predominant feature of MondoA is its ability to sense cellular metabolic states. 
Our work demonstrates that MondoA senses glucose 6-phosphate (G6P) and responds by 
accumulating in the nucleus, binding the promoters of target genes and recruiting 
cofactors to initiate transcription (Peterson et al., 2010; Stoltzman et al., 2008). MondoA 
can sense phosphorylated forms of other nonglucose hexose sugars such as glucosamine, 
2-deoxyglucose and 3-O-methylglucose (Stoltzman et al., 2011). Others have suggested 
that MondoA senses the glycolytic metabolite fructose-2,6-bisphosphate (Petrie et al., 
2013). Petrie et al. proposed that fructose-2,6-bisphosphate induces a transcriptional 
profile that is distinct from G6P-induced transcription. This raises the intriguing 
possibility that MondoA senses multiple glycolytic metabolites, each potentially driving 
the distinct gene expression programs. How broadly MondoA senses glycolytic 
intermediates or potentially other metabolites remains to be explored. 
 Conceptually, by localizing to the OMM, MondoA is poised to sense metabolic 
signals from the mitochondria. Consistent with this idea, steady-state and G6P-stimulated 
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MondoA transcriptional activity requires oxidative phosphorylation (Figure 1.4; (Han and 
Ayer, 2013; Stoltzman et al.; Yu et al., 2010). The exact molecular mechanism that 
controls ETC-sensing by MondoA remains unclear. Yu et al. hypothesized that ETC 
inhibition leads to an increase in glycolytic flux and a decrease in steady-state levels of 
G6P. They found that restricting glycolytic flux through GAPDH inhibition restored 
MondoA activity in the face of ETC inhibition. Yet counter to this argument, 2-
deoxyglucose (2DG), which is a potent inducer of MondoA transcriptional activity under 
most circumstances, does not rescue MondoA activity following ETC inhibition (Yu et 
al., 2010). Thus, glycolytic flux is not the only factor that regulates G6P-driven MondoA 
activity. Our work on 5-amino-4-imidazolecarboxamide (AICAR)-stimulated MondoA 
activity showed that MondoA is a direct sensor of adenine nucleotides (Han and Ayer, 
2013). In Chapters 2 and 3 we show that mitochondrial-derived ATP is the ETC-derived 
signal that drives MondoA activity. 
 MondoA controls the glucose-dependent expression of thioredoxin-interacting 
protein (TXNIP; (Stoltzman et al. 2008). In nearly all cell types, MondoA is necessary 
and sufficient to drive TXNIP expression. MondoA binds a ChoRE in the promoter 
region of TXNIP and recruits cofactors that initiate transcription of TXNIP (Minn et al., 
2005). TXNIP is a potent negative-regulator of glucose uptake (see Chapter 1.3 for a 
detailed discussion of this point). Thus, MondoA and TXNIP form a negative-feedback 
loop that controls glucose homeostasis. As discussed below, the MondoA/TXNIP axis is 
downregulated in many cancers. Furthermore, while not the focus of our current work, 
the MondoA/TXNIP axis is upregulated in insulin-resistance and type-2 diabetes 
(Richards et al., 2017a; Richards et al., 2017b). 
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1.3. The MondoA/TXNIP axis in metabolism and cancer 
1.3.1. The pleiotropic function of TXNIP 
 TXNIP has pleiotropic functions in suppressing cell growth and proliferation 
(Figure 1.5). By restricting thioredoxin (TXN) function, TXNIP drives antiproliferative 
functions such as oxidative stress, DNA damage and ASK1-mediated apoptosis 
(Nishiyama et al., 1999; Palde and Carroll, 2015; Saxena et al., 2010). TXNIP interferes 
with MDM2-mediated p53 ubiquitination and proteolysis, thus driving p53-dependent 
growth suppression and apoptosis (Jung et al., 2013). During quiescence, MondoA-
dependent TXNIP expression is high, enforcing oxidative metabolism; however, 
downregulation of the MondoA/TXNIP axis is essential for cells to exit quiescence, thus 
establishing the MondoA/TXNIP axis as a metabolic checkpoint in the cell cycle (Elgort 
et al., 2010). Further, TXNIP directly inhibits progression through G1 by physically 
interacting with and stabilizing p27(kip1) (Jeon et al., 2005; Yamaguchi et al., 2008). 
Finally, our preliminary data suggests that TXNIP is a negative regulator of PI3K activity 
(our unpublished data). 
 Based on known functions of TXNIP, it has been generally thought that TXNIP 
localizes to the cytoplasm, yet recent work has shown TXNIP is enriched in the nucleus 
and interacts with transcriptional machinery (Huttlin et al., 2017; Huttlin et al., 2015; 
Saxena et al., 2010; Xu et al., 2013). TXNIP stimulates its own expression through a 
feed-forward loop (Chen et al., 2014). Though the mechanism has yet to be fully 
explored, we speculate that TXNIP regulates MondoA function. We address this 
hypothesis in Chapter 4. 
 TXNIP expression is elevated in several rodent models of diabetes and in human 
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diabetes patients (Chen et al., 2010a; Chen et al., 2008a; Chen et al., 2008b). TXNIP 
stimulates activity of the NRLP3 inflammasome, a process that is linked to pancreatic b-
cell death, insulin resistance, and diabetes (Zhou et al., 2010). Further, AMP-activated 
protein kinase (AMPK), a master regulator of b-cell function, is negatively regulated by 
TXNIP expression. Conversely, AMPK phosphorylates TXNIP on residue S308, which 
accelerates its degradation, thus stimulating glucose uptake in an insulin-independent 
manner (Waldhart et al., 2017; Wu et al., 2013). Further work will be important in 
defining the functional connections between AMPK and the MondoA/TXNIP axis. 
 TXNIP has pleiotropic effects on cell metabolism, the most predominant being its 
ability to suppress glucose uptake. Mechanistically, TXNIP localizes to the plasma 
membrane where it binds GLUT1 or GLUT4 and initiates clathrin-mediated 
internalization (Waldhart et al., 2017; Wu et al., 2013). A di-leucine motif in one of the 
arrestin domains of TXNIP is essential for GLUT internalization and probably serves as a 
clathrin binding site. Mutating these residues to alanine leads to constitutive glucose 
uptake (Wu et al., 2013). This is consistent with a report showing that glucose uptake is 
intrinsic to the arrestin-domains (Patwari et al., 2009). Further, TXNIP negatively 
regulates GLUT1 mRNA and protein levels, although the mechanism is not known (Wu 
et al., 2013). A potential explanation is that TXNIP prevents Hypoxia inducible factor 1a 
(Hif1a) transcriptional activity, which drives the GLUT1 expression. Mechanistically, 
TXNIP interacts with and stabilizes an isoform of pVHL that controls the nuclear export 
of Hif1a (Shin et al., 2008). Additionally, TXNIP stabilizes the pVHL/HIF1a 
interaction, facilitating Hif1a ubiquitination and degradation (Yoshioka and Lee, 2014). 
 In addition to its effects on carbohydrate metabolism, TXNIP is an important 
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regulator of lipid homeostasis. TXNIP-knockout mice are hyperlipidemic (Bodnar et al., 
2002). Further, loss of TXNIP in skeletal muscles prevents β-oxidation (DeBalsi et al., 
2014) of a number of substrates. Our recent work has demonstrated that TXNIP decreases 
expression of G0S2, an important negative regulator of lipolysis (our unpublished data). 
Together these results show that TXNIP is important for fatty acid catabolism. 
Paradoxically, one group found that in cardiomyocytes TXNIP negatively regulates fatty 
acid oxidation via the increased expression of miR-33a (Chen et al., 2016). Further work 
will be needed to determine the role of TXNIP in lipid homeostasis. 
 TXNIP is highly upregulated in response to glucose (Shalev et al., 2002; 
Stoltzman et al., 2008). A wide variety of metabolic stresses trigger the MondoA/TXNIP 
axis. In Chapter 2 and 3, we show metabolic rewiring and activation of the 
MondoA/TXNIP axis in response to acidosis and protein synthesis inhibition, 
respectively. Further, endoplasmic-reticulum stress drives TXNIP expression by 
enhancing TXNIP mRNA stability (Lerner et al., 2012). 
 
1.3.2. TXNIP in cancer 
 TXNIP expression is diminished in many cancers including renal, breast, lung, 
gastric, colon and hepatocellular carcinoma (Figure 1.6; (Cadenas et al., 2010; Dutta et 
al., 2005; Kopantzev et al., 2008; Kwon et al., 2010; Lee et al., 2010; Shen et al., 2015; 
Takahashi et al., 2002). TXNIP expression is decreased in triple-negative breast cancer 
(TNBC), and overexpression of TXNIP in patient derived TNBC xenografts restricted 
tumor growth (our unpublished data). However, MondoA and TXNIP have growth 
promoting effects in B-cell acute lymphocytic leukemia (Wernicke et al., 2012). Further 
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work will be needed to determine the contexts in which TXNIP is tumor suppressive 
versus tumor promoting. 
We demonstrated that TXNIP is suppressed by many progrowth pathways. First, 
serum stimulation of cells in quiescence decreases TXNIP expression through the 
Ras/MAPK and PI3K/AKT pathways (Elgort et al., 2010). Second, mTOR physically 
interacts with MondoA and sequesters it from Mlx, thus preventing MondoA-dependent 
TXNIP expression (Kaadige et al., 2015). Third, Myc binds to the TXNIP promoter and 
drives its transcriptionally repression by competing with MondoA at a shared ChoRE 
binding site (Shen et al., 2015). Fourth, constitutively active BRAF represses MondoA-
dependent TXNIP expression (Parmenter et al., 2014). Fifth, Ras decreases translation of 
TXNIP mRNA (our unpublished work). Others have shown that IGF1, PI3K, AKT and 
AMPK all downregulate TXNIP expression (Hong et al., 2016; Nagaraj et al., 2018; 
Waldhart et al., 2017; Wu et al., 2013). By suppressing TXNIP expression, progrowth 
signals drive enhanced glucose uptake and glycolytic metabolism. 
 Our work has focused on TXNIP in triple-negative breast cancer (TNBC). We 
recently demonstrated that MondoA/TXNIP functions as a tumor suppressor axis in 
TNBC. We showed that Myc directly competes with MondoA for a binding site on the 
TXNIP promoter. Restoring TXNIP expression in TNBC restricts glucose uptake and 
aerobic glycolysis (Shen et al., 2015). These findings are consistent with our work 
showing that: 1) high TXNIP expression correlates with better overall prognosis in breast 
cancer patients (Chen et al., 2010b; Shen et al., 2015); 2) overexpression of TXNIP in 
TNBC patient-derived xenografts restricts tumor growth (our unpublished data); and 3) 
loss of MondoA or TXNIP in TNBC leads to increased glucose uptake and proliferation 
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of TNBC cells in culture (data not shown). Collectively, these data suggest that the 
MondoA/TXNIP axis suppresses tumor growth by limiting nutrient availability. Thus 
increasing MondoA/TXNIP activity may be efficacious against TNBC. Consistent with 
these findings, in BRAFV600E melanomas Myc and MondoA also work in opposition. In 
these tumors, activation of the MondoA/TXNIP axis and downregulation of Myc are 
required for the therapeutic efficacy of vemurafenib (Parmenter et al., 2014; Wilde and 
Ayer, 2015). In contrast, in neuroblastoma and Myc-amplified B-cell leukemia, Myc and 
MondoA cooperate to reprogram metabolism and drive tumorigenesis (Carroll and 
Diolaiti, 2016; Carroll et al., 2015). A model that addresses this apparent disparity is that 
as the level of Myc expression determines a requirement for MondoA. When Myc is very 
high, cells need to activate pathways that counter Myc-driven cell death, of which 
MondoA is an integral player. Loss of MondoA thus leads to synthetic lethality. In 
contrast, when Myc is low it needs to rewire transcription to support nutrient uptake to 
allow for cell growth and proliferation. Thus, by repressing MondoA target genes such as 
TXNIP, Myc drives an increase in nutrient uptake and utilization. Chapter 4 specifically 
addresses this model. 
 
1.4. Summary of dissertation 
As reviewed above, MondoA is a sensor of the metabolic status of the cell and 
through its regulation of TXNIP expression, maintains glucose homeostasis. 
Downregulation of the MondoA/TXNIP axis is a hallmark of cancer, and affords cancer 
cells bioenergetic and biosynthetic advantages. Triggering MondoA transcriptional 
activity may be an effective way to target glucose metabolism and treat cancer; however, 
16 
 
this will require characterization of the molecular mechanisms that control MondoA 
transcriptional activity. Further, deep knowledge of the MondoA-dependent 
transcriptome will be important for understanding the downstream consequences of 
restricting MondoA transcriptional activity. 
Chapter 2 addresses how acidosis controls TXNIP expression. We show that 
acidosis drives the synthesis of mitochondrial ATP (mtATP) that is required for MondoA 
transcriptional activity. We further show that the dependence on mtATP is due to its 
consumption by mitochondria-bound hexokinase to generate G6P. This finding 
implicates the mitochondria in transcriptional control of cellular fuel choice. Collectively, 
our findings show that MondoA acts as a coincidence detector, integrating signals from 
glycolysis and the ETC to maintain energy balance in the cell. 
In Chapter 3, we examined the effects of protein synthesis inhibition on the 
MondoA/TXNIP axis. Using the translation inhibitors cycloheximide and Rocaglamide 
A, we observed robust induction of MondoA transcriptional activity. Protein synthesis 
inhibition drives mtATP synthesis and leads to increased G6P levels. Our working model 
is that protein synthesis inhibition drives TCA cycle activity and mtATP synthesis. This 
leads to G6P production by mitochondrial-linked hexokinase and activation of the 
MondoA/TXNIP axis. This model is consistent with the findings in Chapter 2 showing 
that MondoA senses mtATP. Further, we showed that activation of the MondoA/TXNIP 
axis is a key feature of the growth suppressive effects of Rocaglamide A. 
Chapter 4 focused on decoding the MondoA-dependent transcriptome. We used 
CRISPR/Cas9 genome editing to knockout MondoA and TXNIP in two different cell 
lines. mRNA-sequencing and ChIP-sequencing were employed to characterize 
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differentially regulated genes and DNA occupancy, respectively. First, we observed that 
TXNIP supports MondoA transcriptional activity. Second, we showed that MondoA and 
Myc differentially regulate the same genes. Finally, we showed that MondoA is part of an 
adaptive response to high Myc levels. 
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Figure 1.1. Metabolic rewiring in cancer 
Glucose uptake is increased in cancer. Glycolytic intermediates are used to fuel 
biosynthetic pathways including the pentose-phosphate pathway, glycogenesis, fatty acid 
synthesis and serine biosynthesis. Lactic fermentation enhances glycolytic rate by 
generating NAD+. TCA cycle intermediates support biosynthetic pathways, in particular 
fatty acid synthesis. While pyruvate entry into the TCA cycle is decreased, glutamine 





Figure 1.2. The Myc-superfamily of transcription factors 
 (A) The Myc-superfamily of transcription factors are centered on Max and Mlx and 
regulate nutrient utilization. The transcription factors are physically connected by sharing 
binding partners. cMyc, N-Myc and L-Myc all interact with Max. Max also interacts with 
the Mad family of transcriptional repressors, Mnt and Mga. MondoA and MondoB 
(ChREBP) interact with Mlx. Mlx also interacts with Mxd1, Mxd4, Mnt and Mga. (B) 
Diagrams of MondoA and Mlx. MondoA and Mlx interact through the bHLH-Zip and 
dimerization and cytoplasmic localization domains (DCD). MondoA has a strong 
transactivation domain (Cadenas et al., 1957) as well as Mondo-conserved regions 
(MCR), which control nucleocytoplasmic shuttling. MCRs I-IV make up a low-glucose 





Figure 1.3. MCRs II and III control glucose-responsive nucleocytoplasmic shuttling 
Schematics showing (A) overall MondoA structure and the regions where Crm1 and 14-
3-3 bind MondoA, and (B) the consequences of Crm1 and 14-3-3 binding. (C) Molecular 
modeling shows that G6P could coordinate the interaction between ChREBP (green) and 




Figure 1.4. The MondoA/TXNIP axis 
The first committed step of glycolysis is the conversion of glucose into glucose-6-
phosphate, which stimulates MondoA translocation to the nucleus, DNA binding in the 
promoter of target-genes, and recruitment of cofactors to initiate transcription. The most 
well-characterized target gene, TXNIP, negatively regulates glucose uptake. Thus 
MondoA/TXNIP make up a negative-feedback loop that maintains glucose homeostasis 





Figure 1.5. TXNIP is a master regulator of catabolic and anabolic metabolism 
TXNIP controls bioenergetics, biosynthetic and redox metabolism. It directly opposes 
GLUT expression on the plasma membrane. As a negative regulator of AMPK, TXNIP 
prevents lipolysis, glucose uptake, autophagy and mitochondrial biogenesis. It stabilizes 
the interaction of pVHL and Hif1a, thus driving ubiquitination and degradation of Hif1a. 




Figure 1.6. Expression of TXNIP in cancer 
Relative expression of TXNIP as reported in The Cancer Genome Atlas (TCGA). 
Affymetrix U133A microarray was used to quantify expression in cancerous (red) and 
noncancerous tissues (green). Dotted lines indicate average expression level. TXNIP is 
generally decreased in cancer relative to normal tissues. Of note, the most dramatic 













 CHAPTER 2  
 







The MondoA transcription factor and its target-gene thioredoxin-interacting 
protein (TXNIP) constitute a metabolic axis that senses and controls nutrient availability. 
A predominant feature of the MondoA/TXNIP axis is an adaptive response to metabolic 
challenges. The molecular mechanisms that dictate how MondoA senses diverse nutrients 
and stresses are poorly understood. To elucidate these mechanisms, we focused our 
studies on one particular metabolic stress, acidosis, which triggers the MondoA/TXNIP 
axis. We found that acidosis drives mitochondrial ATP (mtATP) synthesis. The 
subsequent export of mtATP from the mitochondrial matrix via adenine-nucleotide 
transporter and voltage-dependent anion channel, and the enzymatic activity of 
mitochondria-bound hexokinase results in the production of glucose-6-phosphate (G6P), 
a potent activator of MondoA transcriptional activity. MondoA localizes to the outer-
mitochondrial membrane (OMM), and in response to G6P, shuttles to the nucleus and 
drives transcription. Thus, the OMM serves as a scaffold for a glucose/mtATP signaling 
center of which MondoA is a central feature. Our findings establish MondoA as a 
coincidence detector, monitoring signals from glycolysis and oxidative phosphorylation. 
Further, we show that MondoA plays a predominant role in the transcriptional response 
to acidosis, and that loss of MondoA prevents the viability of cells exposed to acidosis. 
 
2.2. Introduction 
Glucose is a major source of carbons for the production of ATP and biosynthetic 
intermediates. Dysregulation of glucose uptake and metabolism underlies many diseases 
including cancer and diabetes (Hay, 2016; Petersen et al., 2017). The precise molecular 
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mechanisms that regulate glucose homeostasis in normal and pathological settings are yet 
to be fully explored. 
MondoA is the sentinel regulator of glucose-induced transcription and its activity 
is highly, if not entirely, dependent on glucose (Billin and Ayer; Richards et al. 2017; 
Stoltzman et al. 2008). In response to glucose-6-phosphate (G6P), MondoA shuttles from 
the outer mitochondrial membrane (OMM) to the nucleus where it drives transcriptional 
circuits that control cellular fuel choice (Billin et al., 2000; Sans et al., 2006; Stoltzman et 
al., 2008). A functional electron transport chain (ETC) is also absolutely required for 
MondoA activity, yet the ETC-derived signal remains unknown (Han and Ayer, 2013; Yu 
et al., 2010). Nevertheless, because MondoA responds to both glycolysis and 
mitochondrial respiration, MondoA is poised to be a master regulator of central carbon 
metabolism. 
MondoA controls the glucose-dependent expression of thioredoxin-interacting 
protein (TXNIP), which has a number of critical cellular functions. Among these, the best 
characterized is as a suppressor of glucose uptake. Thus, MondoA and TXNIP make up a 
negative feedback loop that maintains cellular glucose homeostasis. High TXNIP is anti-
correlated with glucose uptake in human tumors and is a predictor of better overall 
survival in cancer patients, establishing the MondoA/TXNIP axis as an important 
prognostic factor in cancer (our unpublished data; Chen et al., 2010; Shen et al., 2015). 
Intracellular acidification is a metabolic stress innate to proliferative cells. Cancer 
cells initiate an adaptive response to intracellular acidification that includes 1) secreting 
protons to the extracellular space, 2) slowing glycolytic flux and 3) restricting glucose 
uptake (Gunnink et al., 2014; Webb et al., 2011). While pH-regulation of glycolytic flux 
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and proton transport have been well studied, it is unknown how intracellular pH regulates 
glucose uptake. We previously showed that lactic acidosis triggers MondoA-dependent 
TXNIP expression and decreased glucose uptake. Further, the suppression of glucose 
uptake following lactic acidosis treatment required both MondoA and TXNIP (Chen et 
al., 2010). Therefore, the MondoA/TXNIP axis is critical for the cellular response to 
lactic acidosis. 
Here we show here that intracellular acidosis drives MondoA-dependent TXNIP 
expression, and requires a functional ETC. Mechanistically, acidosis treatment leads to 
intracellular acidification, hyperpolarizes the mitochondria and leads to increased 
mitochondrial ATP (mtATP) synthesis. As mtATP is exported from the mitochondria, it 
is consumed by mitochondria-bound hexokinase to generate G6P, which subsequently 
activates the MondoA/TXNIP axis. Finally, we observed that MondoA is an essential 
component of the transcriptional response to acidosis, and that loss of MondoA restricts 
adaptive metabolism and cell viability. 
 
2.3. Results 
2.3.1. Intracellular acidosis drives MondoA-dependent TXNIP expression 
Intracellular pH is primarily regulated by the monocarboxylate transporters 
(MCTs) and sodium-hydrogen antiporter 1 (NHE1; (Webb et al., 2011). MCTs are a 
family of plasma membrane transporters that facilitate the cotransport of protons and 
monocarboxylates to the extracellular space. NHE1 controls pH by the electroneutral 
exchange of protons and sodium ions to the extracellular and intracellular space, 
respectively. We used publicly available gene expression data to compare the expression 
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levels of TXNIP and genes that control intracellular pH. TXNIP expression inversely 
correlates with MCT4 in breast cancer, MCT1 in lung cancer and NHE1 in brain cancer 
(Figure 2.1A). TXNIP expression is also anticorrelated with MCTs and NHE1 in 
nontransformed tissues (Figures 2.2A and 2.2B). Further, we identified a correlation 
between TXNIP expression and an acidosis-driven gene-signature in breast cancer 
(Figure 2.1B). 
To better understand how intracellular acidification effects TXNIP expression, we 
treated cells with Hank’s balanced salt solution (HBSS), which mimics the nutrient-poor 
extracellular environment cancer cells are exposed to in vivo. HBSS has minimal pH-
buffering capacity and in 5% CO2 has a pH of ~ 6.4. Consistent with our previous 
findings, HBSS treatment leads to increased TXNIP mRNA and protein expression, and 
also decreases glucose uptake (Figures 2.3A-B and 2.4A; (Chen et al., 2010). HBSS is 
weakly buffered due to its low levels of sodium bicarbonate. We therefore supplemented 
HBSS with sodium bicarbonate to the same level as in DMEM, which raised the pH to 
7.5: this prevented TXNIP induction (Figures 2.3C and 2.4B). To determine whether 
TXNIP induction is mediated by sodium bicarbonate or pH, we clamped the pH to 7.4 by 
adding 25mM HEPES and adjusting the pH with NaOH. This prevented TXNIP 
induction in response to low levels of sodium bicarbonate (Figure 2.3D), confirming that 
low pH is primarily responsible for HBSS-driven MondoA activity. We extended this 
finding to other cell types and media. We observed that low pH DMEM (pH 6.5, 
hereafter referred to as acidosis) induced TXNIP expression in HEK293T, HepG2 and 
HeLa cells (Figure 2.4C). 
Given our findings that MondoA is both necessary and sufficient for TXNIP 
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expression, we sought to determine the requirement for MondoA in HBSS-driven 
TXNIP. We treated MondoA-/- mouse embryonic fibroblasts (MEFs) with HBSS. TXNIP 
was not induced in response to HBSS in MondoA-/- MEFs, yet their reconstitution with 
wild type MondoA rescued TXNIP induction (Figure 2.3E). MondoA requires binding 
with Mlx for its nuclear translocation and DNA binding, and a single point mutation, 
I766P in MondoA, prevents their interaction (Peterson et al., 2010; Stoltzman et al., 
2011). In MondoA-/- MEFs expressing MondoA(I766P), TXNIP was not induced in 
response to HBSS (Figure 2.3E), indicating that HBSS-driven TXNIP is dependent on the 
MondoA:Mlx heterocomplex. 
Since the induction of TXNIP is entirely dependent on MondoA, we hypothesized 
that HBSS drives MondoA transcriptional activity. MondoA binds to the TXNIP 
promoter at a carbohydrate response element (ChoRE), about 80 bp upstream of the 
transcription start site (Minn et al., 2005; Stoltzman et al., 2008). We performed a 
luciferase-reporter assay in which luciferase expression was driven from the TXNIP 
promoter or the TXNIP promoter with a mutation in the ChoRE (ChoRE mut). HBSS 
drove luciferase expression from the wild type promoter, yet we observed no induction of 
luciferase from the ChoREmut promoter (Figure 2.5A). Consistent with this finding, we 
also observed that HBSS treatment led to increased MondoA occupancy of the TXNIP 
promoter (Figure 2.5B). Together these data show that HBSS drives MondoA 
transcriptional activity. 
Previous reports show that treating cells with low pH media for short periods of 
time drives intracellular acidification (Adams et al., 2006; Wahl et al., 2000). pH has 
significant impacts on chemical reactions and macromolecular functions; thus, it is not 
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surprising that organelles greatly vary in their steady-state pH and compartmentalization 
of protons is essential for organelle function (Casey et al., 2010). Therefore, we used 
compartment-selective ionophores to alter proton concentrations in various cellular 
compartments. The monovalent ionophore monensin, which mediates the electroneutral 
exchange of an extracellular Na+ ion for an intracellular proton leading to cytosolic 
alkalization, abrogated HBSS-induced TXNIP expression (Figure 2.6A). By contrast, the 
dibasic ionophore chloroquine that disrupts acidification of endosomes/lysosomes had no 
effect on TXNIP induction (Figure 2.6A). Finally, the mitochondrial ionophore FCCP, 
which uncouples electron transport and ATP generation by the F0F1-ATPase (ATP 
synthase), prevented HBSS-driven TXNIP expression (Figure 2.6B). Together these 
results suggest that mitochondrial proton usage, but not pH-dependent changes in the 
endosome/lysosome, is critical for the activation of the MondoA/TXNIP axis. 
 
2.3.2. MondoA is dependent upon mitochondrial ATP 
We next sought to evaluate the impact of the ETC on the MondoA/TXNIP axis 
using a genetic approach. To accomplish this, we used r0 cells that lack mtDNA and are 
respiration deficient. TXNIP was induced in 143B osteosarcoma cells treated with 
acidosis (Figure 2.7A); however, acidosis driven TXNIP expression was blunted in 
143B⍴0 cells (Figure 2.7B). Repopulating 143B⍴0 cells with wild type mitochondria 
rescued TXNIP induction (Figure 2.7C). These results illustrate MondoA’s dependence 
on a functional ETC.  
ETC complexes I-IV cooperatively build a proton gradient by pumping protons 
from the mitochondrial matrix to the inner membrane space. ATP synthase harnesses the 
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resultant proton motive force to phosphorylate ADP. We therefore hypothesized that 
acidosis leads to intracellular acidification, hyperpolarization of the inner-mitochondrial 
membrane and ATP production. We measured intracellular pH using the pH-sensitive 
dye BCECF-AM. We observed that acidosis treatment shifted intracellular pH from 7.2 
to 6.5 (Figure 2.7D). This was accompanied by an increase in mitochondrial membrane 
potential as measured by JC1 (Figure 2.7E). Further, acidosis drove an increase in total 
cellular ATP levels (Figure 2.7F). Collectively these data suggest that acidosis drives 
ATP synthesis, which may support MondoA transcriptional activity. 
A number of recent publications have demonstrated that measuring metabolic 
changes from whole cells may be vastly different from what is observed at specific 
organelles (Abu-Remaileh et al., 2017; Chen et al., 2016). We therefore sought to 
determine how acidosis affects mitochondrial ATP (mtATP).  To accomplish this, we 
used a mitochondrial-targeted fluorescence resonance energy transfer (FRET) ATP 
biosensor (Mit-ATEAM). This biosensor consists of cp173-Venus fused to mseCFP via 
an ATP-binding linker region (Imamura et al., 2009). As a control, we used constructs 
with mutations in the ATP binding domain that prevent ATP binding and FRET signaling 
(Figure 2.10A-2.10F). HeLa cells treated with acidosis showed increased FRET signal 
over time, indicating that acidosis drives an increase in mtATP (Figures 2.9A and 2.10C). 
We next determined whether mtATP synthesis is required to trigger the 
MondoA/TXNIP axis. The ATP synthase inhibitor oligomycin completely blocked 
TXNIP induction in response to acidosis or HBSS (Figures 2.6A and 2.6B). We next 
used 143B⍴0:DATP6/DATP8 cybrid cells, which have a single point mutation in mtDNA 
that causes ATP8 truncation and disruption of the ATP6 start codon (Boominathan et al., 
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2016; Jonckheere et al., 2008). These cells lack expression of both ATP6 and ATP8 and 
thus lack a functional ATP synthase. Acidosis-driven TXNIP expression was blunted in 
these cells (Figure 2.9C), but ATP synthase and TXNIP induction is partially rescued by 
nuclear-encoded versions of ATP6 and ATP8 that are targeted to the mitochondria 
(Boominathan et al., 2016) (Figure 2.9C). Similarly, knock down of nuclear-encoded 
ATP5I, an essential component of the ATP synthase (Figure 2.9B), prevented TXNIP 
induction in response to acidosis (Figure 2.9D).  Importantly, ATP5I knock down 
decreased the steady state level and the acidosis-driven increase in mtATP (Figures 2.9E 
and 2.11A). These data show that acidosis drives mtATP production through the ATP 
synthase and that mATP synthesis correlates with TXNIP induction. 
 
2.3.3. MondoA senses G6P produced by mitochondrial-hexokinase 
Mitochondria-bound hexokinase has preferential access to mtATP that is exported 
from the mitochondria (Wilson, 2003). Thus, enhanced mtATP synthesis and export from 
the mitochondria leads to increased production of G6P, which is a potent activator of 
MondoA transcriptional activity. We speculated that an increase in mtATP synthesis 
would drive G6P production and trigger the MondoA/TXNIP axis. We used GC/MS to 
determine how acidosis treatment affects central carbon metabolism. While there was a 
general decrease in glycolytic intermediates, we observed a significant increase in steady 
state G6P levels (Figure 2.12A). 
MondoA, Mlx and HK2 are all residents of the outer mitochondrial membrane 
(Figure 2.12C; Sans et al., 2006). We speculated that increase in mtATP production and 
export would lead to increased utilization by mitochondrial-bound HK2 to generate G6P, 
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which could then activate mitochondria-localized MondoA (Figure 2.12B). To test this 
model, we blocked export of mtATP. In HeLa cells, the most highly expressed 
mitochondrial transporter of ATP is ANT2 (SLC25A5). Using siRNA, we blunted 
expression of ANT2. This prevented TXNIP induction (Figure 2.12D), suggesting that 
export of mtATP from the mitochondria is critical for acidosis-driven MondoA activity. 
siRNA pools against HK2 also blocked TXNIP induction (Figure 2.12E). Overexpression 
of HK2(D657A), which lacks kinase activity, also blocked TXNIP induction (Figure 
2.12F). 
Hexokinase localizes to the outer-mitochondrial membrane via interactions the 
voltage-dependent anion channel (VDAC; (Wilson, 2003). The N-terminal 25 amino 
acids of hexokinase and Glu72 of VDAC1 are necessary for hexokinase/VDAC 
interaction. Mutating VDAC-E72 prevents the VDAC/hexokinase interaction and 
disrupts the mitochondrial localization of hexokinase (Abu-Hamad et al., 2008; Zaid et 
al., 2005). To address the requirement of mitochondrial-localization of hexokinase for 
induction of the MondoA/TXNIP axis, we overexpressed a mutant version of the mouse 
orthologue of VDAC1, mVDAC1(E72Q), which has a dominant negative effect on 
hexokinase localization to the mitochondria. As expected, we observed a decrease in 
mitochondrial-localization of HK2, and complete loss of acidosis-driven TXNIP (Figure 
2.12G). 
We next sought to rescue the effect of mVDAC1(E72Q). To accomplish this goal, 
we artificially tethered HK2 to the mitochondria in a manner completely independent of 
the N-terminal 25 amino acids of HK2, which is its known mitochondrial tether, and 
Glu72 of VDAC. We tagged mVDAC1 with the first 10 b-strands of GFP (mVDAC1-
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GFP(1-10)) and tagged HK2 with the last b-strand of GFP (HK2-GFP(11)). When 
coexpressed, the b-strands of GFP self-assemble, linking mVDAC1 and HK2 (Figure 
2.12H). Notably, neither mVDAC1-GFP(1-10) nor HK2-GFP(11) alone fluoresce, but 
when assembled, fluorescence is observed in a mitochondrial pattern (Figure 2.13A). 
Mirroring the results with mVDAC1(E72Q) from above, overexpression of 
mVDAC1(E72Q)-GFP(1-10) alone decreases the amount of HK2 on the mitochondria 
and prevents TXNIP induction (Figures 2.12H and 2.12I). However, coexpression of 
mVDAC1(E72Q)-GFP(1-10) and HK2-GFP(11) rescues HK2 mitochondrial localization 
and TXNIP induction (Figures 2.12H and 2.12I). Together these data show that 
mitochondrial-localized HK2 is both necessary and sufficient for acidosis-driven 
MondoA activity. 
 
2.3.4. MondoA is a predominant feature of an adaptive response to acidosis 
 We next determined the impact of acidosis on MondoA-dependent transcription. 
Using CRISPR/Cas9 genome editing, we knocked out MondoA in HeLa cells 
(HeLa:MondoA-KO cells). This was done by expressing CRISPR/Cas9, three sgRNAs 
and a homology-directed repair (HDR) construct containing a puromycin-resistance 
cassette. HDR incorporation into the MondoA locus conferred puromycin resistance. We 
confirmed the loss of MondoA expression by immunoblot analysis (Figure 2.14A). We 
next conducted mRNA-sequencing on parental and HeLa:MondoA-KO cells treated with 
normal media or acidosis. We determined the genes that are differentially regulated by 
acidosis each cell type. Using a log2(fold change) greater than one, parental cells had 169 
differentially regulated genes, about 50% of which were not differentially regulated in 
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HeLa:MondoA-KO cells (Figure 2.14B), indicating that MondoA is an essential feature 
of the adaptive response to acidosis. Using overrepresentation analysis, we determined 
that acidosis drives an adaptive immune response and cholesterol biosynthesis, of which 
cholesterol biosynthesis is specific to MondoA (Figure 2.14C). Finally, loss of MondoA 
decreased the viability of HeLa cells treated with acidosis (Figure 2.14D). Together these 
data indicate that MondoA is a necessary component of an adaptive response to acidosis. 
 
2.4. Discussion 
In describing key features of metabolic rewiring in cancer, Otto Warburg noted 
that increased sodium bicarbonate and increased pH favor glycolysis (Koppenol et al., 
2011; Warburg, 1925). Intracellular alkalization is now a widely accepted hallmark of 
cancer metabolism (Webb et al., 2011), and has pleiotropic effects on tumorigenesis, the 
most predominant being a transition from oxidative metabolism to aerobic glycolysis 
(Reshkin et al., 2000). A central feature of this conversion to aerobic glycolysis is an 
increase in glucose uptake (Xie et al., 2014). Consistent with this observation, the 
MondoA/TXNIP axis is suppressed under alkaline conditions. By contrast, the 
MondoA/TXNIP axis is activated by acidosis. Thus, we propose that the 
MondoA/TXNIP axis plays a critical role in how cells sense and respond to dysregulated 
glycolytic metabolism and pH. 
Changes in cytosolic pH influence multiple aspects of mitochondrial function 
(Matsuyama and Reed, 2000; Wu et al., 2017). During intracellular acidification protons 
can contribute to the proton gradient at the mitochondria (Wu et al., 2017). Additionally, 
chronic acidosis increases mitochondrial-membrane potential and enhances oxidative 
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phosphorylation (Khacho et al. 2014). These findings are consistent with our data 
showing that acidosis treatment causes intracellular acidification, hyperpolarization of the 
inner-mitochondrial membrane and ATP production. 
We previously showed that MondoA senses G6P and the ETC; however, the 
specific ETC derived signal was unknown. Multiple hypotheses have been put forward to 
explain the dependence of MondoA on ETC, the predominant being that ETC inhibitors 
cause increased glycolytic flux and decreased steady state G6P levels, thus restricting 
G6P-stimulated MondoA. Inhibiting the glycolytic enzyme GAPDH rescued TXNIP 
from blockade in ETC activity. Yet coadministration of ETC inhibitors and 2-
deoxyglucose, a glycolytic inhibitor, does not rescue MondoA activity, suggesting that 
the mechanism involves more than only glycolytic flux (Yu et al., 2010). By dissecting 
acidosis-induction of MondoA transcriptional activity, we discovered that MondoA 
senses mitochondrial ATP (mtATP). Further, we show that as mtATP is exported from 
the mitochondria, it becomes a substrate in the production of G6P by mitochondria-bound 
hexokinase. Our findings establish MondoA as a coincidence detector, which 
simultaneously senses mtATP and glucose through the generation of G6P.  Conceptually, 
by detecting mitochondrial ATP and cytosolic glucose metabolism, MondoA is poised to 
be a master regulator of central carbon metabolism. The mechanistic details of how 
MondoA senses G6P and the impact on cell metabolism remains to be clarified. 
MondoA, Mlx and hexokinase all localize to the outer-mitochondrial membrane 
where they make up a nutrient sensing center. Mitochondria-bound hexokinase 
preferentially uses mtATP, thereby coupling G6P production to mtATP availability. By 
binding to the mitochondria, hexokinase has increased specific activity and decreased 
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feedback inhibition by G6P (Robey and Hay, 2006). By localizing to the mitochondria 
and sensing G6P derived from mitochondria-bound hexokinase, we propose that 
MondoA couples its activity to mitochondrial metabolism and oxidative phosphorylation. 
Our results show that mtATP pools instead of cytosolic pools of ATP control MondoA 
transcriptional activity, illustrating that not all pools of ATP are equal. It further 
illustrates that site-specific ATP synthesis is an important determinant in controlling 
nutrient homeostasis. 
TXNIP expression is downregulated by progrowth signals such as mTOR, PI3K, 
Ras and Myc (Elgort et al., 2010; Kaadige et al., 2015; Shen et al., 2015). We previously 
showed that TXNIP repression is essential for enhanced glucose uptake and a shift away 
from mitochondrial metabolism toward aerobic glycolysis. The resultant decrease in 
mtATP synthesis further restricts MondoA transcriptional activity and TXNIP 
expression. This feed-forward restriction of TXNIP enforces high glucose availability to 
support the metabolic demands of growing cells. We propose that reactivating the 
MondoA/TXNIP axis would restrict aerobic glycolysis and cell proliferation. One 
potential approach would be to drive intracellular acidification by inhibiting NHE1 with 
amiloride, which has antiglycolytic and anticancer properties (Reshkin et al., 2000; Xue 
et al., 2010). 
We show that the MondoA/TXNIP axis is a predominant feature of an adaptive 
response to intracellular acidification. In particular MondoA is essential for acidosis-
driven expression of cholesterol biosynthesis genes. This finding is consistent with other 
data showing that MondoA drives expression of genes involved in cholesterol 
biosynthesis (Carroll et al., 2015). The full impact of MondoA/TXNIP axis on cholesterol 
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biosynthesis remains to be explored. During tumor development, there are multiple times 
in which cells experience pH-related metabolic stress. Additional studies will be 
important in determining the impact of the MondoA/TXNIP axis on an adaptive response 
to intracellular acidification in vivo and the impact on tumorigenesis. 
 
2.5. Experimental methods 
2.5.1. Experimental model and subject details 
A list of cell lines used is provided in the Key Resources Table. All cells were 
maintained in DMEM +10% FBS (Gibco), 100 units/mL penicillin (Gibco) and 100 
units/mL streptomycin (Gibco). MDA-MB-231 were additionally cultured with non-
essential amino acids. 143Br0 and cybrids were cultured with 1 mM sodium pyruvate and 




HBSS was supplemented with glucose to 20 mM prior to treatment. Acidosis 
treatment media was prepared from DMEM powder without glutamine, glucose, 
pyruvate, sodium bicarbonate and phenol red. The following were added: glutamine to 2 
mM, glucose to 20 mM, pyruvate 1 mM, sodium bicarbonate to 0.35 g/L and phenol red 






2.5.3. Plasmid construction 
Plasmids were created using either standard restriction digest and ligation or 
Gibson assembly (NEB). A list of plasmids used, the vector backbone and their source is 
provided in the Key Resources Table. 
 
2.5.4. Quantitative PCR 
Total RNA was extracted from cells using a Quick RNA Miniprep Kit (Zymo 
Research) according to manufacturer’s recommendations. cDNA was synthesized from 
200 ng mRNA using the GoScript Reverse Transcription System (Promega) with oligo-
dT primers. A 100-fold dilution was used in a PCR reaction containing SYBR Green and 
analyzed on a CFX Connect Real Time System. Values were determined by a standard 




Equal concentrations of denatured protein lysates were resolved on 10% SDS-
PAGE gel with a stacking gel. Proteins were electrotransferred to PDVF membrane 
(Genesee Scientific). Membranes were incubated in 5% (weight/volume) blotting-grade 
nonfat dry milk (Bio-Rad) in TBST (Tris-buffered saline, pH 7.4 and 0.1% Tween-20) 
for 30 minutes at room temperature with gentle rocking. Membranes were then 
transferred to antibody-dilution buffer (20 mM Tris, pH 8.0; 200 mM NaCl; 0.25% 
Tween-20; 2% bovine serum albumin; 0.1% sodium azide) and incubated for one hour at 
room temperature or overnight at 4 °C with gentle rocking. Membranes were washed 
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with TBST and vigorous rocking at room temperature. Membranes were then incubated 
in secondary antibody diluted in 5% (weight/volume) blotting-grade nonfat dry milk 
(Bio-Rad) in TBST for one hour at room temperature with gentle rocking. Membranes 
were then washed again and proteins were detected with chemiluminescence using 
standard or high sensitivity ECL (Genesee Scientific or Thermo Fisher, respectively). 
Antibodies were used at the following dilutions: Anti-GFP 1:1000; Anti-HK2 1:1,000; 
Anti-Mlx 1:1,000; Anti-MondoA 1:2,000; Anti-SDHA 1:15,000; Anti-Tubulin 1:50,000; 
Anti-TXNIP 1:2,000; Anti-goat HRP 1:20,000; Anti-mouse HRP 1:5,000 and Anti-rabbit 
HRP 1:15,000. 
 
2.5.6. ATP quantification 
After treatment, cells were washed once with cold PBS. Cells were scraped into 
boiling TE buffer (1 mL per 3.5 cm dish), which was collected into 1.5 mL centrifuge 
tube. Cells were then boiled at 100°C for five minutes. Tubes were then spun at 20,000xg 
for five minutes. 10 µL of supernatant was used for analysis. ATP determination kit 
(Thermo Fisher) was used to detect ATP. A standard curve was generated using purified 
ATP. 
 
2.5.7. Glucose uptake 
Cells were incubated with deoxy-D-glucose-2[1,2-3H(N)] (American 
Radiolabeled Chemicals, Inc.) in KRH buffer (NaCl,116 mM; KCl, 4 mM; MgCl2, 1 
mM; CaCl2, 1.8 mM; 2-deoxy-D-glucose, 20 mM; HEPES pH 7.4, 10 mM) for 10 
minutes. Cells were then washed, harvested and analyzed for radioactivity using a 
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scintillation counter. A standard was used to determine the exact molar content in each 
sample. deoxy-D-glucose-2[1,2-3H(N)] was normalized to protein content as determined 
by a Bradford Protein Assay (Bio-Rad).  
2.5.8. Cell viability/proliferation 
Cells were seeded in 6-well dishes (1000 cells/well). When cells were harvested, 
media was aspirated and 1 mL of crystal violet staining solution was added to wells 
(0.05% crystal violet, 1% formaldehyde and 1% methanol in PBS). Plates were rocked 
gently at room temperature for one hour. Staining solution was then aspirated and water 
was used to wash wells several times until washes came out clear. Plates were then dried 
overnight. 
To quantify crystal violet retention, 1 mL of 1% SDS in H2O was added to each 
well. Plates were rocked gently at room temperature for one hour. Supernatant from each 
well was analyzed by absorbance spectroscopy at 590 nm. Values were only considered if 
absorbance was £ 0.90. If absorbance was higher, samples were diluted in 1% SDS in 
H2O. 
2.5.9. Mitochondrial membrane potential 
Cells were plated on 8-well Nunc™ Lab-Tek™ II Chambered Coverglass 
(Thermo Fisher). Forty-five minutes prior to experiment, cells were preloaded with JC1 
(1 µg/mL). Cells were treated acidosis media lacking phenol red or DMEM lacking 
phenol red. A Nikon A1 confocal and NIS Elements AR were used to capture images 
over the course of four hours. For each time point images were captured by exciting with 
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488 nm and reading emission at 530 nm (green) and 595 nm (red). The ratio of red to 
green is used to quantify changes in membrane potential. JC1 signal was dramatically 
reduced one hour after treatment; therefore, the one-hour time point was used to report 
mitochondrial membrane potential. 
2.5.10. Intracellular pH 
Cells were plated on 3.5 mm glass bottom culture dishes (MatTek Corporation). 
The next day cells were treated with normal or low pH DMEM for four hours. Cells were 
treated with BCECF-AM (1 µM) 30 minutes prior to the end of the experiment. A 
standard curve was generated by treating cells with Nigericin (5 µM) and media of 
varying pHs for 30 minutes prior to BCECF-AM treatment. A Nikon A1 confocal and 
NIS Elements AR were used to capture images by exciting with 488 nm and reading 
emission at 530 nm and 595 nm. The 595/530 nm fluorescence emission ratio was used to 
generate a calibration curve and determine intracellular pH for acidosis-treated cells. 
2.5.11. Mitochondria purification 
Mitochondria were purified from ~20×106 cells using a Mitochondria Isolation 
Kit for Cultured Cells (Thermo Fisher). Cells were processed using the dounce 
homogenation method. Following purification, mitochondria were resuspended in 100 µl 
radioimmunoprecipitation buffer. 100 µl of both mitochondria and cytosolic fractions 
were sonicated at using a Bioruptor sonication device. Sonication was performed 4°C 
using 30 second on/off pulses at the high setting. Following sonication, lysates were 
centrifuged and supernatants were collected and analyzed for protein content using a  
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Bradford Protein Assay (Bio-Rad). 1-5 µg of sample were used for immunoblot analysis. 
2.5.12. Luciferase assay 
Cells were seeded and the next day transfected with constructs containing TXNIP 
promoter (or a mutant)-driven luciferase and CMV-driven beta-galactosidase. Cells were 
harvested in 1X Buffer RLB (Promega). Luciferase was detected using the Luciferase 
Detection System (Promega), and beta-galactosidase was detected using Galacto-Light™ 
Reaction Buffer Diluent with Galacto-Plus™ Substrate (Thermo Fisher). Luminescence 
was determined using a GloMax 96 Microplate Luminometer (Promega). Luciferase 
values were normalized to beta-galactosidase. 
2.5.13. GC-MS 
Following treatment, cells were collected into a 1.5 mL microcentrifuge tube then 
snap frozen using liquid nitrogen. Cells were kept at -80°C until metabolite extraction 
was performed. 450 µL of cold 90% methanol and internal standards were added to cells 
and incubated at -20°C for one hour. Tubes were then centrifuged at -20,000×g for five 
minutes at 4°C. Supernatants were dried using a speed-vac. 
Samples were converted into volatile derivatives amenable to GC-MS. Briefly, 
dried samples were resuspended in O-methoxylamine hydrochloride (40 mg/mL) then 
mixed with 40 µL N-methyl-N-trimethylsilyltrifluoracetamide and mixed at 37°C. After 
incubation, 3 µL fatty acid methyl ester standard solution was added. One µL of this 
final solution was injected into gas chromatograph with an inlet temperature of 250°C. A 
10:1 split ratio was used. Three temperatures were ramped with a final temperature of 
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350°C  and a final three-minute incubation. A 30 m Phenomex ZB5-5 MSi column was 
used. Helium was used as carrier gas at 1 mL/minute. Samples were analyzed again 
with a 10-fold dilution. 
Data was collected using MassLynx 4.1 software (Evan et al., 1992). Metabolites 
were identified and peak area was determined using QuanLynx. Data was normalized 
using Metaboanalyst 3.6 (http://www.metaboanalyst.ca/). Quantile normalization, log 
transformation and Pareto scaling were used. Normal distribution of values was used to 
determine fold changes. 
2.5.14. RNA-sequencing library construction and analysis 
Total RNA was extracted from cells using a Quick RNA Miniprep Kit (Zymo 
Research) according to manufacturer’s recommendations. mRNA was isolated and 
library production performed using a Stranded mRNA-Seq Kit with mRNA Capture 
Beads (Kapa). Library quality was analyzed using an Agilent High Sensitivity D1000 
ScreenTape. Single-end sequencing for 50 cycles was performed using an Illumina 
HiSeq. The resulting FASTQ files were aligned to the human genome (hg19) using 
Novoalign. DESeq2 was used to quantify transcript abundance and differential 
expression. 
Overrepresentation analysis was performed using ConsensusPathDB. Pathway-
based sets were analyzed from Wikipathways. A p-value cutoff of 0.01 and a minimum 
overlap of 2 genes was used. Enriched pathways were verified by comparing fold-
changes obtained from DESeq2. 
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2.5.15. Live cell imaging: Widefield microscopy 
Widefield microscopy was used for Figures 2.9 and 2.11. Cells were plated on 3.5 
mm glass bottom culture dishes (MatTek Corporation). The following day 100 ng DNA 
was transfected using Lipofectamine 3000 (Thermo Fisher) according to manufacturer’s 
recommendations. The next day cells were treated acidosis media lacking phenol red. A 
Nikon [scope info] with a 40X lens and [camera] was used to capture images over the 
course of eight hours. For each time point we took images using / (YFP), / (CFP), and / 
(FRET) excitement/emission. 
Images were analyzed using ImageJ. We used the YFP channel to identify and 
isolate mitochondrial regions for each image. We isolated these same regions from the 
CFP and FRET channel. Total intensity was determined for each image. FRET/CFP 
ratios were determined and normalized to the two-hour time point. RatioPlus was used to 
make pseudo-colored images. 
2.5.16. Live cell imaging: Confocal microscopy 
Confocal microscopy was used for Figure 2.10. Cells were plated on 8-well 
Nunc™ Lab-Tek™ II Chambered Coverglass (Thermo Fisher). The following day 200 
ng DNA was transfected using Lipofectamine 3000 (Thermo Fisher) according to 
manufacturer’s recommendations. The next day cells were treated acidosis media lacking 
phenol red or DMEM lacking phenol red with CCCP. A Nikon [scope info] with a 20X 
lens and [camera] was used to capture images over the course of eight hours. For each 
time point we took images using / (YFP), / (CFP), and / (FRET) excitement/emission. 
Images were analyzed using ImageJ. RatioPlus was used to make pseudo-colored images. 
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Total intensity was determined. 
2.5.17. Gene signature 
mRNA expression z-scores were obtained for 2509 breast cancer tumors (Pereira 
et al., 2016). Acidosis regulated genes were determined from the gene set 
GO_RESPONSE_TO_ACIDIC_PH in the Molecular Signature Database. Principal 
component analysis was conducted for all tumors using the expression levels of acidosis 
regulated genes. Gene signature scores were determined as the first principle component. 
This was compared to TXNIP expression for the same tumors. 
2.5.18. Quantification and statistical analysis 
Data is presented as mean ± standard deviation. One-way ANOVA was used to 
account for variation and significance was determined using a two-tailed Student’s t-test. 
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Table 2.1. Key Resources 
REAGENT or RESOURCE SOURCE IDENTIFIE
R Antibodies 
Anti-GFP (B-2) Santa Cruz sc-9996 
Anti-HK2 (anti-HXKII) Santa Cruz sc6521 
Anti-MLX (D8G6W) Cell Signaling 85570S 
Anti-MondoA (Anti-MLXIP) Proteintech 13614-1-AP 
Anti-SDHA [2E3GC12FB2AE2] Abcam AB147 
Anti-Tubulin Molecular Probes 236-10501
Anti-TXNIP Abcam ab188865 
Donkey anti-goat IgG-HRP Santa Cruz sc-2056 
Mouse IgG, HRP-linked whole Ab (from 
sheep) 
GE Life Science NA-931 
Rabbit IgG, HRP-linked whole Ab (from 
donkey) 
GE Life Science NA-934 
Chemicals, Peptides, and Recombinant Proteins 
BCECF-AM Thermo Fisher B1170 
Blotting Grade Blocker Non-fat Dry Milk Bio-Rad 1706404XT
U 
CCCP Sigma Aldrich C2759 
Chloroquine Sigma Aldrich 415480 




DMEM Gibco 11995-065 
DMEM Powder without sodium bicarbonate, 
glucose, L-glutamine, sodium pyruvate and 
phenol red 
Cellgro 90-113-PB
DMEM, no glucose Gibco 11966025 
DMSO Fisher BP231 
FCCP Sigma Aldrich C2920 
Fetal bovine serum (FBS) Gibco 26140-079 
Galacto-LightTM Reaction Buffer Diluent with 
Galacton-PlusTM
Thermo Fisher T1055 
Glucose Fisher D16-1 
Glutamine Cellgro 25-005-Cl
HBSS Gibco 24020-117 
HCl Fisher A144SI-212 
HEPES Sigma Aldrich H3375 
JC1 Thermo Fisher T3168 
Luciferase Assay System Promega E4550 
Metformin Sigma Aldrich D150959 
Monensin Sigma Aldrich M5273 
more 
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Table 2.1. continued. 
NaOH Fisher S-320-1
Non-essential amino acids Gibco 11140-050 
Oligomycin A Sigma Aldrich 75351 
Pennicillin/Streptomycin Gibco 15140-112 
Phenol Red Sigma Aldrich P-0290
ProSignal Pico ECL Genesee Scientific 20-300B
Reporter 5X Lysis Buffer Promega E4030 
Sodium bicarbonate Fisher L-23200
Sodium pyruvate Gibco 11360-070 
SuperSignal West Femto Thermo Fisher 34094 
Trypsin-EDTA (0.25%) Gibco 25200-056 
Tween-20 Fisher BP-337 
Critical Commercial Assays 
Quick RNA miniprep kit Genesee Scientific R1055 
ATP determination kit Thermo Fisher A22066 
Mitochondria isolation kit for cultured cells Thermo Fisher 89874 
Stranded mRNA-Seq kit with mRNA capture 
beads 
Kapa Biosystems KK8421 
Experimental Models: Cell Lines 
MondoA -/- mouse embryonic fibroblasts Peterson et al. 2008 N/A 
MondoA D/D mouse embryonic fibroblasts Peterson et al. 2008 N/A 
143B Weinberg et al. 2010 N/A 
143Br0 Weinberg et al. 2010 N/A 
143Br0:Wild type cybrid Weinberg et al. 2010 N/A 
143Br0:DCYTB cybrid Weinberg et al. 2010 N/A 
143Br0:DATP6/DATP8 cybrid Boominathan et al. 
2016 
N/A 
143Br0:DATP6/DATP8 cybrid + ATP6nuc 
+ATP8nuc 




MDA-MB-231 ATCC HTB-26 
BJ-Tert ATCC CRL-4001 
MDA-MB-231:MondoA-KO1 This paper N/A 
MDA-MB-231:MondoA-KO2 This paper N/A 




Peterson et al. 2010 N/A 
TXNIP_reverse (human): 
TTGCGCTTCTCCAGATACTGC 
Peterson et al. 2010 N/A 
TXNIP_forward (mouse): 
CCTGACCTAATGGCACC 








Peterson et al. 2010 N/A 
ATP5I_forward: 
CAGGTCTCTCCGCTCATCAAG 
This paper N/A 
ATP5I_reverse: 
GCCCGAGGTTTTAGGTAATTGT 
This paper N/A 
Actin_forward: 
TCCATCATGAAGTGTGACGT 
Peterson et al. 2010 N/A 
Actin_reverse: 
TACTCCTGCTTGCTGATCCAC 
Peterson et al. 2010 N/A 
Recombinant DNA 
LXSH Stoltzman et al. 
2008 
N/A 
LXSH-MondoA Stoltzman et al. 
2008 
N/A 
LXSH-MondoA(I766P) Stoltzman et al. 
2008 
N/A 
pcDNA3-AT1.03 (ATEAM) Imamura et al. 2009 N/A 
pcDNA3-mitAT1.03 (Mit-ATEAM) Imamura et al. 2009 N/A 
pcDNA3-AT1.03 R122K/R126K Imamura et al. 2009 N/A 
pcDNA3-mitAT1.03 R122K/R126K Imamura et al. 2009 N/A 
pEGFP-N1-mVDAC1 Zaid et a. 2005 N/A 
pEGFP-N1-mVDAC1(E72Q) Zaid et a. 2005 N/A 
pCDV-SPORT6-HK2 Stoltzman et al. 
2008 
N/A 
pCDV-SPORT6-HK2(D657A) Stoltzman et al. 
2008 
N/A 
pcDNA3.1-mVDAC1-GFP(1-10) This paper N/A 
pcDNA3.1-mVDAC1(E72Q)-GFP(1-10) This paper N/A 
pcDNA3.1-HK2-GFP(11) This paper N/A 
pGL3Basic-TXNIP_Promoter Peterson et al. 2010 N/A 
pGL3Basic-TXNIP_Promoter(ChoREmut) Peterson et al. 2010 N/A 
Software and Algorithms 
Prism Graphpad Software N/A 
ImageJ N/A N/A 
CFX Manager 3.1 Bio-Rad N/A 
R N/A N/A 
NIS Elements Nikon N/A 
Other 
siRNA: Dharmacon ON-TARGETplus control 
siRNA 
GE Life Sciences D00-1810-
10-20 




Table 2.1. continued. 
 
siRNA: siATP5I SmartPool GE Life Sciences M-019688-
01 
siRNA: siSLC25A5 SmartPool (siANT2) GE Life Sciences M-007486 
siRNA: siHK2 SmartPool GE Life Sciences L-006735-
00-0005 
NuncTM Lab-TekTM II Chambered Coverglass, 
8-well 
Thermo Fisher 155409PK 
3.5 mm glass bottom culture dishes MatTek Corporation P35G-.15-
14-C 
Hybond P PVDF Membrane; 0.45 µm Genesee Scientific 83-646R 
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Figure 2.1. TXNIP expression anticorrelates with genes that control intracellular pH 
(A) Heatmaps depicting the expression of TXNIP mRNA compared to MCT4 (breast
cancer), MCT1 (lung cancer) and NHE1 (brain cancer). All expression data was collected
from TCGA. Spearman and Pearson correlation statistics are reported as r and ρ,
respectively. (B) An acidosis gene signature was determined for the 2016 METABRIC
breast cancer dataset. These scores were compared to TXNIP expression from the dataset




Figure 2.2. Supplement: TXNIP expression anticorrelates with genes that control 
intracellular pH 
Heatmaps depicting the expression of TXNIP mRNA compared to MCT4, MCT1 and 
NHE1 for normal (A) skin and (B) muscle tissues. All expression data was collected from 




Figure 2.3. Acidosis drives MondoA-dependent TXNIP expression 
Mouse embryonic fibroblasts (MEFs) treated with HBSS for the indicated amounts of 
time and (A) TXNIP mRNA levels were determined by reverse transcriptase-quantitative 
PCR (RT-qPCR) and (B) TXNIP and MondoA protein levels were determined 
immunoblotting. (C) TXNIP mRNA from MEFs treated with DMEM, HBSS and HBSS 
supplemented with sodium bicarbonate to the same level as in DMEM (3.7 g/L). HBSS 
with high sodium bicarbonate brought the pH to 7.5. (D) TXNIP protein levels in MEFs 
treated with DMEM and HBSS containing the indicated amounts of sodium bicarbonate. 
Additionally, the same treatments were clamped to pH 7.4 by adding 25mM HEPES and 
adjusting pH with NaOH. (E) Immunoblot examining TXNIP induction in response to 
HBSS in MondoA-knockout MEFs complemented with empty vector, wild type MondoA 




Figure 2.4. Supplement: HBSS drives MondoA-dependent TXNIP expression 
(A) Glucose uptake was determined by quantifying the rate of H3-2-deoxyglucose uptake 
in cells treated with HBSS. (B) TXNIP immunoblot of MEFs treated with DMEM, HBSS 
and HBSS supplemented with sodium bicarbonate to the same degree as DMEM (3.7 





Figure 2.5. Supplement: The MondoA/TXNIP axis is triggered by acidosis 
(A) Schematic depicting luciferase reporter assay. A construct was made that contained a 
mutation in the carbohydrate-responsive element (ChoREmut). Luciferase constructs were 
transfected into MEFs and HBSS treatment results in a slight induction of luciferase. 
Using the ChoREmut TXNIP promoter, initial luciferase expression was lower and HBSS 
treatment had no effect on luciferase. (B) Chromatin-immunoprecipitation performed on 
MEFs treated with HBSS. Antibodies against MondoA and IgG were used. 
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Figure 2.6. Supplement: TXNIP induction by HBSS occurs through regulation of 
mitochondrial protons 
(A) TXNIP protein levels in MEFs treated with ionophores chloroquine (Chlor., 25 µM)
and monensin (Mon., 5 µM), which cause lysosomal and cytosolic alkalization,
respectively. (B) TXNIP protein levels in MEFs treated with HBSS and the
mitochondrial ionophore FCCP or the ETC complex inhibitors metformin (Met., 1 mM)




Figure 2.7. Acidosis drives ETC-dependent MondoA transcriptional activity 
TXNIP mRNA level following treatment with acidosis in (A) 143B osteosarcoma cells, 
(B) 143Br0 cells, which lack mtDNA, and (C) WT-Cybrid cells, which have restored 
wild type mitochondria. (D) Intracellular pH was determined by BCECF-AM staining. 
(E) Mitochondrial membrane potential was determined by JC1 staining. (F) Relative 
ATP levels were determined using an ATP-luciferase assay. * p<0.05; ** p<0.01; 




Figure 2.8. Supplement: Acidosis-driven MondoA activity requires the ATP 
synthase 
(A) TXNIP mRNA levels in HeLa cells after treatment with the ETC poisons metformin 
(complex I, 5 mM), rotenone (complex I, 1 µM), NaN3 (complex IV, 1 mM) and CCCP 
(disrupts the proton gradient, 1 µM). (B) TXNIP protein levels in MEFs treated with the 
mitochondrial ionophore FCCP and the ETC complex inhibitors metformin (Met., 1 mM) 
and oligomycin (Olig., 1 µM). 
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Figure 2.9. MondoA senses mitochondrial ATP 
(A) Mit-ATEAM, a mitochondrial-targeted ATP-biosensor, was used to determine how
acidosis affects mitochondrial ATP. Widefield microscopy was used to capture images in
the FRET and CFP channels. After images were obtained, mitochondria were analyzed
for FRET and CFP signal. FRET signal was normalized using CFP. (B) A schematic
depicting nuclear- and mitochondrial-DNA encoded components of the ETC. (C) TXNIP
mRNA level following treatment with acidosis of 143Br0:DATP6/ATP8-Cybrid cells,
which do not express ATP6 or ATP8, critical components of the ATP synthase. Empty
vector or mitochondrial-targeted versions of the ATP6 and ATP8 were expressed. The
dotted line indicates the level to which TXNIP was induced in 143Br0:WT-cybrid cells.
(D) TXNIP mRNA level following acidosis treatment of HeLa cells expressing
scrambled or ATP5I-specific siRNA (siSCRM or siATP5I). ATP5I knock down was
confirmed by measuring ATP5I mRNA levels. (F) Mit-ATEAM was used to determine
how acidosis affects mitochondrial ATP production in the context of siSCRM or




Figure 2.10. Supplement:  Acidosis drives mitochondrial ATP synthesis 
(A) Confocal images at 60X of Mit-ATEAM expressed in HeLa cells. Shown are the 
CFP and FRET channels as well as the ratio of FRET to CFP (indicating ATP). (B) 
Widefield image at 60X of ATEAM. CFP channel only is shown. (C) Confocal images of 
Mit-ATEAM and Mit-ATEAM(R122K/R126K) in HeLa cells. Cells were treated with 
acidosis or CCCP (1 µM) for eight hours. Images are pseudo-colored according to the 
FRET/CFP ratio and (D) quantification is given. (E) Confocal images of ATEAM and 
ATEAM(R122K/R126K) in HeLa cells. Cells were treated with acidosis or CCCP (1 
µM) for eight hours. Images are pseudo-colored according to the FRET/CFP ratio and (F) 
quantification is given. Notably, the FRET/CFP ratios for Mit-ATEAM(R122K/R126K) 
and ATEAM(R122K/R126K) was negligible compared to nonmutated constructs. 
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Figure 2.11. Supplement: Acidosis drives mitochondrial ATP synthesis 
(A) Widefield microscopy of Mit-ATEAM was used to determine how acidosis affects
mitochondrial ATP production in the context of siSCRM or siATP5I. Shown are pseudo-















Figure 2.12. MondoA senses G6P produced by mitochondrial-hexokinase 
(A) Heatmap and log2 fold-changes of glycolytic and TCA metabolites measured from 
HeLa cells treated for four hours with acidic media using GC-MS. (B) Schematic 
illustrating how mtATP could contribute to MondoA transcriptional activity. As mtATP 
is exported from the mitochondria, mitochondrial-bound HK2 consumes it to produce 
G6P, resulting in MondoA activation. (C) Cellular fractionation of BJ-Tert cells 
indicating mitochondrial localization of Hk2, MondoA and Mlx. Succinate 
dehydrogenase A (SDHA) serves as a control for the mitochondria fraction. TXNIP 
mRNA levels of HeLa cells treated with acidosis and expressing a pool of four siRNAs 
against (D) ANT2 and (E) HK2, or (F) expressing HK2 and HK2(D657A). (G) TXNIP 
mRNA levels of BJ-Tert cells treated with acidosis and expressing mVDAC1-GFP and 
mVDAC1(E72Q)-GFP. HK2 localization was also analyzed by cellular fractionation and 
densitometry was used to quantify the relative amount of HK2 on the mitochondria. Of 
note, HK2 became increasingly enriched in the cytoplasmic fraction. (H) Schematic 
depicting the use of GFP(1-10) and GFP(11) to artificially tether mVDAC1 and HK2. 
HK2 localization was also analyzed by cellular fractionation, and densitometry was used 
to quantify the relative amount of HK2 on the mitochondria. (I) TXNIP mRNA levels of 
BJ-Tert cells treated with acidosis and expressing mVDAC1-GFP, mVDAC1(E72Q)-






Figure 2.13. Supplement: MondoA senses G6P produced by mitochondrial-
hexokinase 
(A) Schematic depicting the use of GFP(1-10) and GFP(11) as a means of artificially
tethering mVDAC1 and HK2 in the cell. Images of GFP signal in HeLa cells transfected
with (B) TXNIP-GFP(11) and GFP(1-10) used as a positive control for alpha
complementation, (C) HK2-GFP(11), (D) GFP(1-10) and HK2-GFP(11), (E) mVDAC1-
GFP(1-10), (F) mVDAC1-GFP(1-10) and HK2-GFP(11), (G) mVDAC1(E72Q)-GFP(1-




Figure 2.14. The MondoA-dependent acidosis response 
(A) Schematic depicting the strategy employed to knock out MondoA in HeLa cells. In 
brief, three sgRNAs, CRISPR/Cas9 and a homology construct were expressed. 
Homology-directed repair resulted in incorporation of a puromycin-resistance cassette. 
Puromycin was used to select for a pool of cells in which MondoA was lost. Immunoblot 
showing loss of MondoA. Of note, consistent with our previous findings, loss of MondoA 
prevented TXNIP expression. (B) RNA-sequencing was used to determine differentially 
regulated genes for HeLa and HeLa:MondoA-knockout cells treated with acidosis. (C) 
Over-representation analysis was used to determine the pathways that initiated by 
acidosis treatment. In gray are the pathways that lost in HeLa:MondoA-KO cells, 
indicating a dependence on MondoA. (D) Relative cell proliferation of cells treated with 




Figure 2.15. Model 
A model depicting our findings. Acidosis drives mtATP synthesis. HK2 has preferential 
access to mtATP exported through ANT and VDAC. This leads to increased G6P 
synthesis, which activates MondoA. Finally, MondoA drives transcriptional circuits that 





 CHAPTER 3 
DIRECT ACTIVATION OF THE MONDOA/TXNIP 
AXIS BY PROTEIN SYNTHESIS INHIBITORS 
79 
3.1. Abstract 
Although protein synthesis is tightly linked to nutrient availability, crosstalk 
between the ribosome and metabolic pathways is poorly understood. Here we describe a 
mechanism by which protein synthesis exerts control over glucose uptake. Using protein 
synthesis inhibitors, we show that the MondoA/TXNIP axis, which restricts glycolytic 
flux, is activated by a blockage of  protein synthesis. This is primarily due to significant 
metabolic rewiring that leads to mitochondrial ATP (mtATP)generation. mtATP is 
exported from the mitochondria and consumed by mitochondria-bound hexokinase 
produces glucose-6-phosphate, which is a potent activator of the MondoA/TXNIP axis. 
Further, we show that the anticancer protein synthesis inhibitor, Rocaglamide A, requires 
TXNIP for its antiproliferative efficacy. Finally, we observed that the MondoA/TXNIP 
axis is necessary for an adaptive response to protein synthesis inhibition. These findings 
provide a mechanistic link between the rate of protein synthesis, mitochondrial ATP 
synthesis, the MondoA/TXNIP axis and glucose availability. 
3.2. Introduction 
A unifying characteristic of oncogenes is their ability to drive anabolic 
metabolism to support the biosynthesis of macromolecules. Oncogenes also impose 
significant metabolic stress on cells (Hsieh and Dang, 2016). As a result of increased 
protein synthesis, cancer cells experience depletion of local nutrient supplies, 
accumulation of ROS, and many other metabolic challenges that if unchecked would 
result in cell death. In order to prevent apoptosis, the ribosome must convey information 
about translation flux to the pathways that control nutrient availability. Recently protein 
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synthesis inhibitors have received attention as potential anticancer therapies. Inhibitors of 
translation initiation are among the most promising candidate therapies (Martineau et al., 
2014; Santagata et al., 2013). Yet the full mechanistic and biological consequences of 
targeting translation initiation have not been described. 
 The MondoA/TXNIP axis is a nexus of glucose homeostasis. Mechanistically, 
glucose-6-phosphate (G6P) drives translocation of the MondoA transcription factor from 
the outer mitochondrial membrane (OMM) to the nucleus where it binds DNA in the 
promoters of its target genes and recruits cofactors that initiate transcription. We recently 
showed that MondoA also requires mtATP for its transcriptional activity. An important 
target gene of MondoA is TXNIP, a negative regulator of glucose uptake. Previous 
reports have shown that protein synthesis inhibitors drive TXNIP expression, yet the 
mechanistic details remain unknown (Santagata et al., 2013). 
 Here we report that protein synthesis inhibitors activate the MondoA/TXNIP axis 
and restrict glucose uptake. Protein synthesis inhibitors cause widespread metabolic 
rewiring, including increased synthesis of mtATP, which is as a substrate for the 
production of G6P by mitochondria-bound hexokinase. The resultant increase in G6P 
drives MondoA transcriptional activity and TXNIP expression. We showed that the 
induction of the MondoA/TXNIP axis common among many protein synthesis inhibitors, 
including the elongation-initiation inhibitor Rocaglamide A (RocA). Importantly, the 
ability of RocA to restrict cell growth depends on its ability to initiate a transcriptional 
response by the MondoA/TXNIP axis. These findings expand our understanding of 
adaptive metabolism in response to protein synthesis inhibition. Further, it reinforces our 
previous findings that the MondoA/TXNIP axis is a metabolic switch that senses diverse 
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signals to control nutrient homeostasis. 
 
3.3. Results 
3.3.1. Translation inhibition drives TXNIP expression 
 Protein synthesis inhibitors drive expression of TXNIP (Santagata et al., 2013). 
To examine the generality of this finding, we performed an unbiased analysis of genes 
that correlate with TXNIP expression using the Gene-tissue Expression Database 
(GTEx). We identified a positive correlation between TXNIP and eukaryotic elongation 
factor 2 kinase (EEF2K), which negatively regulates mRNA translation elongation by 
phosphorylating and inactivating eukaryotic elongation factor 2 (Figures 3.1A and 3.2A; 
(White-Gilbertson et al., 2009). In contrast, we observed that EIF4A1 and EIF4E, both 
essential components of the elongation initiation machinery, were anticorrelated with 
TXNIP expression (Figure 3.2B). We extended these findings to cancerous tissues and 
observed that in breast cancers, TXNIP negatively correlates with elongation-initiation 
factor EIF4G1 and the ribosomal biogenesis genes RRP12 and RRP1 (Figure 3.1B). 
These data support the general model that a high rate of translation suppresses TXNIP 
expression. 
 We previously showed that mTOR is a negative regulator of the MondoA/TXNIP 
axis and that treating cells with mTOR inhibitors leads to induction of TXNIP expression 
(Kaadige et al., 2015). Given that enhanced protein synthesis is a predominant feature of 
mTORC1 activity, we investigated how protein synthesis inhibitors affect the 
MondoA/TXNIP axis. Treating HeLa cells with cycloheximide (CHX), which interferes 
with the translocation step of protein synthesis, led to a robust induction of TXNIP. In 
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comparison, the effects of the mTOR inhibitor, Torin, on TXNIP expression were more 
modest (Figure 3.1C), suggesting that CHX induces TXNIP via a pathway parallel to 
mTOR. We extended this finding to nontransformed cell lines including C2C12 and L6 
myoblasts and HEK293 embryonic kidney cells, and found in all cases that CHX drove 
TXNIP expression (Figures 3.3A-C). 
 Given that oncogenes repress the MondoA/TXNIP axis, we sought to determine 
how CHX affects TXNIP expression in a variety of transformed cells. CHX drove 
TXNIP expression in HRAS(G12V)-transformed MEFS, TSC2-/- MEFs and 
MYC(T58A)-overexpressing MDA-MB-231 cells (Figures 3.1D-E and 3.3D). Finally, 
emetine and puromycin, which block translation elongation, also increased TXNIP 
expression (Figure 3.1F). Together, these findings demonstrate that TXNIP is induced 
broadly in response to protein synthesis inhibition, and suggest that TXNIP can be 
induced independent of oncogenic events. It is possible that the MondoA/TXNIP axis is 
1) a sensor of protein synthesis and 2) a component of an adaptive response pathway 
initiated by a blockade in protein synthesis. We therefore investigated the mechanism by 
which protein synthesis inhibitors induce TXNIP expression. 
 
3.3.2. Protein synthesis inhibitors drive MondoA transcriptional activity 
 We evaluated the contribution of MondoA to TXNIP induction by protein 
synthesis inhibitors. We treated wild type and MondoA-/- mouse embryonic fibroblasts 
(MEFs) with CHX. In the absence of MondoA, CHX treatment did not induce expression 
of TXNIP or another MondoA target gene, ARRDC4, a TXNIP paralogue (Figures 3.4A 
and 3.5A). Ectopic expression of MondoA rescued TXNIP induction in MondoA-/- MEFs 
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(Figure 3.4B). MondoA:Mlx heterodimerization is necessary for translocation to the 
nucleus and DNA binding (Peterson et al., 2010). Expressing MondoA(I766P), which is 
unable to bind Mlx, did not rescue CHX-driven TXNIP expression (Figure 3.4B), 
illustrating the requirement for functional MondoA:Mlx heterocomplexes. Consistent 
with this observation, we observed increased nuclear localization of MondoA in response 
to CHX when analyzed by immunofluorescence (Figure 3.4C). We evaluated the 
occupancy of MondoA on the promoter of TXNIP by chromatin immunoprecipitation 
(ChIP). CHX treatment led to increased occupancy of MondoA on the TXNIP promoter 
(Figure 3.4D). 
 MondoA-dependent TXNIP expression is mediated by a CACGAG carbohydrate-
response element about 80 bp upstream of the transcription start site (Minn et al., 2005). 
MondoA:Mlx binds to the ChoRE and recruits cofactors to initiate transcription (Peterson 
et al., 2010). We used a TXNIP luciferase reporter assay to evaluate ChoRE-dependent 
transcription (Figure 3.4E). Cells were treated with CHX and one hour prior to 
determining luciferase expression, we washed out CHX by replacing the media with fresh 
glucose-free DMEM. This allowed for accumulated luciferase mRNA to be translated. 
Cells treated with CHX had increased luciferase activity, and this effect was entirely 
dependent on an intact ChoRE (Figure 3.4F). Thus, protein synthesis inhibition drives 
MondoA transcriptional activity. 
 
3.3.3. Metabolic rewiring by protein synthesis inhibition 
 Because MondoA is a glucose dependent transcription factor, we determined the 
requirement for glucose in CHX-driven TXNIP expression. HeLa cells were treated with 
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CHX in DMEM or glucose-free DMEM. Surprisingly, TXNIP was induced in the 
presence and in the apparent absence of glucose (Figure 3.6A). FBS contains glucose 
(about 5 mM), which may provide a source of glucose to support MondoA-dependent 
TXNIP expression. This did not seem to be the case in our previous studies (Peterson et 
al., 2010; Stoltzman et al., 2008). We dialyzed FBS to remove small molecules including 
glucose then treated cells with CHX in glucose-free DMEM + 10% dialyzed FBS. This 
prevented the induction of TXNIP in response to CHX (Figure 3.6B). Adding glucose 
back rescued TXNIP induction (Figure 3.6C). In addition to greatly increasing the 
expression of TXNIP at all glucose levels, CHX decreased the glucose threshold ~ 5 fold 
at which TXNIP expression is induced. Thus, protein synthesis inhibitors sensitize the 
MondoA/TXNIP axis to low levels of glucose. 
 Given that MondoA transcriptional activity is tightly linked to nutrient 
abundance, in particular abundance of G6P and mtATP, we sought to determine how 
inhibiting protein synthesis affects the metabolic state of the cell. GC-MS was used to 
evaluate metabolite levels in cells treated with CHX. We observed significant changes in 
the levels of glycolytic intermediates and TCA cycle intermediates (Figures 3.6D and 
3.6E and data not shown). G6P levels were significantly enriched following CHX 
treatment (Figure 3.6E), thus accumulated G6P likely explains why protein synthesis 
inhibitors trigger the MondoA/TXNIP axis. Considering that the increase in G6P was 
much greater than that observed for other glycolytic intermediates, we hypothesized that 





3.3.4. Protein synthesis inhibition drives mtATP production 
 We previously showed that MondoA is a sensor of mtATP in Chapter 2. We first 
investigated the requirement of the TCA cycle for CHX-driven TXNIP expression. We 
addressed this question by treating cells with dichloroacetic acid (DCA), an inhibitor of 
PDH kinase. DCA prevents phosphorylation and inactivation of PDH, thus increasing in 
the amount of pyruvate that is metabolized in the TCA cycle. DCA treatment further 
increased CHX-driven TXNIP (Figure 3.7A). Conversely, by using pyruvate-free media 
CHX-driven TXNIP expression was blunted (Figure 3.7B). Glutamine can also be a 
source of carbons for the TCA cycle, therefore we used glutamine-free and 
pyruvate/glutamine-free media. While glutamine-free media had no effect, 
pyruvate/glutamine-free media prevented CHX-driven TXNIP expression (Figure 3.7B). 
 Pyruvate and glutamine are anaplerotic substrates that are converted to 
oxaloacetate and a-ketoglutarate, respectively. Dimethyl-a-ketoglutarate (DMK) and 
oxaloacetate (OAA) supplementation rescued the depletion in CHX-driven TXNIP 
expression caused by withdrawing pyruvate and glutamine (Figure 3.7C). NAD+, which 
is used as a substrate in the TCA cycle, was able to rescue the decrease in TXNIP 
induction caused by withdrawing pyruvate and glutamine (Figure 3.8A). Finally, we 
treated HeLa cells with CHX and the ETC inhibitors metformin (ETC complex I 
inhibitor) or oligomycin (ATP synthase inhibitor). Inhibiting oxidative phosphorylation 
disrupted CHX-driven TXNIP induction (Figure 3.7D). Together these data demonstrate 
the importance of the TCA cycle and oxidative phosphorylation in protein synthesis 
inhibition-driven TXNIP expression. 
 We next determined how protein synthesis inhibition affects mtATP. We 
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expressed a mitochondrial-targeted ATP FRET-biosensor (Mit-ATEAM) in HeLa cells 
and used live cell imaging to quantify fluorescence. CHX treatment caused massive cell 
death (data not shown) and could not be used for these experiments. Instead we used a 
different protein synthesis inhibitor, Rocaglamide A (RocA), which targets the 
elongation-initiation factor EIF4A. RocA induces TXNIP expression to the same degree 
as CHX (Figure 3.9A). Inhibiting protein synthesis by RocA lead to increased FRET 
signal indicating accumulation of ATP in the mitochondria (Figure 3.9B). We next used 
siRNA to deplete levels of ATP5I, an essential component of the ATP synthase. This 
prevented CHX-driven TXNIP expression (Figure 3.9C). Together these data suggest that 
protein synthesis inhibition triggers the MondoA/TXNIP axis by increasing mitochondria 
ATP synthesis. 
 
3.3.5. Elongation initiation and the MondoA/TXNIP axis 
 Dysregulation of mRNA translation is a hallmark of cancer and is induced by 
numerous oncogenes (Ali et al. 2017). Eukaryotic translation initiation factors (eIFs) are 
commonly overexpressed in cancer and several oncogenes converge on the activation of 
eIFs (Ali et al., 2017). It is therefore thought that inhibiting elongation initiation may 
selectively target and eradicate cancer cells. We therefore asked whether inhibiting 
elongation initiation triggers the MondoA/TXNIP axis. 
 We knocked down EIF4E in HeLa cells using siRNA. EIF4E depletion led to an 
increase in TXNIP mRNA levels (Figure 3.10A). Surprisingly, TXNIP protein levels 
dramatically increased as well (Figure 3.10B). This suggests that TXNIP may undergo 
cap-independent translation. Consistent with this, it was recently shown that TXNIP 
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undergoes both cap-dependent and IRES-mediated translation (Lampe et al., 2018). 
Considering that TXNIP is induced by inhibiting elongation initiation, and that 
translation of TXNIP occurs in a cap-independent manner, we hypothesized that drugs 
targeting elongation initiation would induce both TXNIP mRNA and protein. 
 Rocaglates are a class of phytochemicals that selectively kill cancer cells, the 
most common being Rocaglamide A (RocA). RocA targets EIF4A and converts it to a 
sequence-selective translation inhibitor by increasing EIF4A/mRNA affinity and 
blocking scanning of the preinitiation complex (Iwasaki et al., 2016). Low nanomolar-
doses of RocA induced TXNIP expression in HeLa cells (Figure 3.10C), which led to a 
decrease in glucose uptake (Figure 3.11B). RocA also drove an increase in TXNIP 
protein levels in the triple-negative breast cancer cells (TNBC) cell lines MDA-MB-157 
and MDA-MB-231 (Figure 3.10D). 
 We next asked whether the MondoA/TXNIP axis is required for RocA to suppress 
growth. Using shRNAs, we blunted TXNIP expression in MDA-MB-157 cells. We then 
treated cells with 100 nM RocA for three days and determined relative cell viability using 
crystal violet staining. We observed that TXNIP knock down protected MDA-MB-157 
cells from growth suppression by RocA (Figure 3.10E). In line with this finding, TXNIP-
/- MEFs were also less susceptible to RocA than wild type MEFs (Figure 3.12A). These 







3.3.6. MondoA/TXNIP in a RocA-induced stress response 
 We next determined the role of MondoA/TXNIP in the growth suppression 
initiated by RocA treatment. Using CRISPR/Cas9 genome editing we knocked out 
MondoA and TXNIP in HeLa cells (Figure 3.13A). We next conducted mRNA-
sequencing on cells treated with RocA to determine the differentially regulated genes for 
each cell type. MondoA and TXNIP are responsible for 23% and 16% of the RocA-
dependent gene expression signature, respectively (Figure 3.13B). As expected TXNIP 
was highly induced by RocA and its expression was highly dependent on MondoA 
(Figure 3.13C). ARRDC4 induction was less robust but was also MondoA-dependent 
(Figure 3.13C). By comparing the Log2Fold-Change for each cell type we identified a 
novel MondoA/TXNIP regulated gene, Ras-related Associated with Diabetes (RRAD; 
Figures 3.13C-E), which was induced upon treatment with RocA in HeLa but not in 
HeLa:MondoA-KO and HeLa:TXNIP-KO cells (Figures 3.13C-E). RRAD is a negative 
regulator of glycolysis and may work collaboratively with TXNIP and ARRDC4 to 
suppress glycolysis following RocA treatment (Casey et al., 2008; Liu et al., 2015; Shang 
et al., 2016; Yan et al., 2016; Zhang et al., 2014). 
 
3.4. Discussion  
 The ribosome is centrally situated to process and transmit information throughout 
the cell. Translational flux is tightly linked to nutrient availability, yet how the ribosome 
conveys the need for increased nutrients has remained unknown. Here we describe a 
mechanism by which the protein synthesis exerts control over the MondoA/TXNIP axis 
and glucose uptake. 
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 We and others previously showed that the MondoA/TXNIP axis is tightly linked 
to metabolic reprogramming. MondoA simultaneously senses glucose and mtATP 
through the production of G6P by mitochondria-bound hexokinase (see Chapter 2). Here 
we show that a blockade in protein synthesis leads to metabolic rewiring, including an 
increase in mtATP synthesis and overall levels of G6P, leading to activation of the 
MondoA/TXNIP axis.  
 The anticancer translation inhibitor RocA drove an increase in TXNIP protein 
levels and a decrease in glucose uptake. We showed that the MondoA/TXNIP axis is a 
critical component of the growth suppressive properties of RocA. This is consistent with 
our finding that constitutive TXNIP expression in TNBC patient derived xenografts 
suppresses tumor growth in vivo (data not shown). These finding illustrate that activating 
the MondoA/TXNIP axis may have clinical benefit in suppressing tumor growth, and that 
RocA may be a way to achieve this. Importantly, protein synthesis inhibitors appear to 
drive TXNIP expression regardless of the oncogenic insult. The in vivo effects of RocA 
on the MondoA/TXNIP axis and its role in cytotoxicity remain to be determined. 
 We determined the RocA-induced, MondoA-dependent changes in gene 
expression. This analysis revealed that TXNIP and ARRDC4 are the most highly 
MondoA-dependent genes following RocA treatment. Our findings here indicate that 
MondoA/TXNIP axis controls a significant portion of the adaptive response to protein 
synthesis inhibition. By examining the lists for dysregulated transcripts that showed 
dependence on MondoA or TXNIP, we identified RRAD as a potential target.  
 In conclusion our studies showed that protein synthesis regulates the 
MondoA/TXNIP axis. Inhibiting protein synthesis rewires metabolism. Further 
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experiments will be needed to determine the mechanism by which MondoA senses G6P. 
 
3.5. Experimental procedures 
3.5.1. Cell culture 
 Cells were incubated at 37 °C in 5% CO2. DMEM with penicillin/streptomycin 
and 10% FBS (Gibco) was used for murine embryonic fibroblasts, HeLa, MDA-MB-231, 
L6, C2C12 and 293T (all from ATCC) and MDA-MB-157 cells (a gift from Andrea Bild, 
University of Utah). TSC2-/- and TSC2-/-:hTSC2 MEFs are a gift of Brendan Manning, 
Harvard University. MondoA-/- MEFs were created from Day 15 embryos as described 
previously (Stoltzman et al., 2011).  
 
3.5.2. Plasmids 
 pcDNA3.1-MondoA-V5, pcDNA3-Mlx-FLAG, LXSH-MondoA, and LXSH-
MondoA(I766P) as well as TXNIP promoter luciferase reporter plasmids (wild type and 
ChoRE mutant) were described (Sans et al., 2006; Stoltzman et al., 2011). pcDNA3-Mit-
ATEAM (pcDNA3-mitAT1.03) was a gift of Hiroyuki Noji, Rikkyo University 
(Imamura et al., 2009). pLKO.1-shScrm and pLKO.1-shTXNIP were obtained from 
Sigma Aldrich. Standard molecular cloning techniques were used to generate pLVX-
TetOne-Puro-MYC(T58A). Transfections were performed using Lipofectamine 2000 






3.5.3. Protein synthesis inhibitor treatments 
 Media was replaced with glucose-free DMEM with penicillin/streptomycin and 
10% FBS for six hours.  Media was then replaced with glucose-free DMEM with 
penicillin/streptomycin, 10% FBS, and translation inhibitors for 16 hours. Unless 
otherwise indicated, compounds were added at the following concentration: 
Cycloheximide (Sigma Aldrich), 50 µg/ml; emetine (Sigma Aldrich), 50 µg/ml; 
puromycin (Sigma Aldrich), 100 µg/ml; and Rocaglamide A (Santa Cruz), 25-100 nM.  
Serum dialysis experiment? 
 
3.5.4. Quantitative real-time PCR 
 Total RNA was extracted using the RNAeasy Kit (Qiagen). cDNA was 
synthesized from 0.1-1 µg RNA using GoScript reverse transcription kit (Promega). 
qPCR was performed using OneTaq Hot Start DNA Polymerase (Heidelberger et al., 




 Cells were transfected with plasmids containing MondoA-V5 and FLAG-Mlx 
using Lipofectamine 2000 (Thermo Fisher). Following treatment, cells were fixed on 
glass coverslips using ice-cold 100% methanol for 15 minutes, following which we 
followed standard immunofluorescence procedures. Mouse anti-V5 (Thermo Fisher) 





 GC-MS was used to determine metabolite levels as described previously (Chapter 
2). Five biological replicates were used for each treatment type. 
 
3.5.7. Chromatin immunoprecipitation 
 MondoA-V5 was transfected into cells. Chromatin was cross-linked and sheared 
as in Peterson et al. 2010. Chromatin was incubated overnight with anti-V5 antibody 
(Thermo Fisher) or mouse IgG (Sigma Aldrich). M-280 sheep anti-mouse Dynabeads 
(Thermo Fisher) were used to capture and purify immunocomplexes. DNA was purified 
using a QIAquick PCR Purification Kit (Qiagen) and analyzed using quantitative PCR as 
described above. Primers were previously described (Shen et al., 2015). 
 
3.5.8. Promoter activity assay 
 TXNIP promoter luciferase assays were performed as described previously 
(Stoltzman et al., 2008). 
 
3.5.9. FRET 
 Widefield microscopy was used to conduct live cell imaging on cells expressing 
Mit-ATEAM as described previously (Chapter 2). 
 
3.5.10. Immunoblotting 
 Immunoblotting was performed as described previously (Kaadige et al., 2015). 
Primary antibodies were used at a dilution of 1:1000 anti-MLXIP (Proteintech, 13614-1-
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AP), 1:2000 anti-VDUP1 (MBL, K0205-3), 1:15,000 anti-Tubulin (Molecular Probes, 
236-10501) and 1:1,000 anti-EIF4E (BioLegend, 693002). Secondary were used at a 
dilution of 1:5000 anti-rabbit (GE Life Sciences, NA-934) and 1:15,000 anti-mouse (GE 
Life Sciences, NA-931). 
 
3.5.11. Cell viability assay 
 Crystal violet was used to determine relative cell viability/proliferation as 
described previously (Chapter 2). 
 
3.5.12. Statistical methods 
Data represents the mean ± S.D. for five biological replicates for metabolomics 
experiments and three biological replicates for all other experiments. ANOVA was 
performed to determine significance. 
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Figure 3.1. TXNIP induction by protein synthesis inhibitors 
Heatmaps representing TXNIP mRNA levels relative to (A) EF2 kinase in skin tissues 
(GTEx), and (B) EIF4G1 (elongation initiation), RRP12 (ribosomal biogenesis) and 
RRP1 (ribosomal biogenesis) in breast cancer (TCGA). Pearson and Spearman 
correlation statistics are reported below. (C) TXNIP mRNA levels in HeLa cells 
following treatment with CHX (50 µg/mL) or Torin (250 nM). TXNIP mRNA levels 
after CHX treatment of (D) normal or HRAS(G12V)-transformed MEFs, (E) TSC2-/- 
MEFs expressing empty vector or human-TSC2. Cells were treated with 50 µg/mL CHX 
for 16 hours. (F) TXNIP mRNA levels in HeLa cells after treatment with the translation 






Figure 3.2. Supplement: TXNIP expression correlates with genes that control 
mRNA translation 
Heatmaps representing mRNA levels of TXNIP relative to (A) EF2 kinase (GTEx: all 
tissues), and (B) EIF4A1 and EIF4E (GTEx: skin). Pearson and Spearman correlation 




Figure 3.3. Supplement: Protein synthesis inhibitors induce TXNIP expression 
TXNIP mRNA levels following CHX treatment of (A) C2C12 mouse myoblasts, (B) L6 
rat myoblasts, (C) 293T embryonic kidney cells, and (D) MDA-MB-231 expressing tet-
inducible MYC(T58A) with or without doxycycline. TXNIP mRNA levels following 
CHX treatment of HeLa cells with varying (E) pretreatment glucose-starvation time, (F) 




Figure 3.4. Protein synthesis inhibition drives MondoA transcriptional activity 
TXNIP mRNA levels following CHX treatment of (A) MondoA+/+ and MondoA-/- MEFs, 
and (B) MondoA-/- MEFs expressing empty vector, MondoA or MondoA(I766P). 
Notably, MondoA(I766P) cannot interact with its obligate partner Mlx. (C) 
Immunofluorescence was used to assess the localization of MondoA in response to CHX. 
(D) Depiction of TXNIP-promoter luciferase reporter constructs. Wild type or ChoREmut 
TXNIP promoter was directly upstream of TXNIP. (E) HeLa cells expressing luciferase 
constructs were treated with CHX for 16 hours. One hour prior to assessing cells for 
luciferase activity, we washed out CHX by replacing media with glucose-free DMEM. 
This allowed for translation of accumulated luciferase message. (F) Chromatin-
immunoprecipitation was used to determine the enrichment of MondoA on the TXNIP 




Figure 3.5. Supplement: Protein synthesis inhibition drives MondoA transcriptional 
activity 




Figure 3.6. Metabolic rewiring after treatment with protein synthesis inhibitors 
Prior to treatment with protein synthesis inhibitors, cells were starved of glucose for six 
hours. This ensure that TXNIP levels were at a minimum. We then measured TXNIP 
mRNA levels in HeLa cells treated with CHX in (A) DMEM or glucose-free DMEM + 
10% FBS, (B) glucose-free DMEM + 10% FBS or dialyzed FBS, and (C) glucose-free 
DMEM + 10% dialyzed FBS + varying amounts of glucose. (D) GC-MS was used to 
assess metabolite levels in HeLa cells treated with CHX. Of note, CHX has a broad 
impact on all metabolic pathways we analyzed. (E) Log2(fold change) of glycolytic and 





Figure 3.7. CHX-driven TXNIP expression requires the  TCA cycle 
(A) TXNIP mRNA levels in HeLa cells treated with CHX and dichloroacetic acid 
(DCA), which inhibits PDH kinase, thus enhancing pyruvate metabolism in the TCA 
cycle. TXNIP mRNA levels in HeLa cells treated with CHX in (B) glucose-free DMEM 
with or without pyruvate and glutamine, and (C) glucose-free DMEM without pyruvate 
or glutamine, and supplemented with dimethyl-a-ketoglutarate (DMK) and oxaloacetate 
(OAA). (D) TXNIP mRNA levels in HeLa cells treated with CHX and electron transport 




Figure 3.8. Supplement: CHX-driven TXNIP expression requires TCA cycle 
(A) TXNIP mRNA levels following CHX treatment of HeLa cells in glucose-free 
DMEM, glucose-free DMEM without pyruvate (P) or glutamine (Q), glucose-free 




Figure 3.9. Protein synthesis inhibition drives mitochondrial ATP synthesis 
(A) TXNIP mRNA levels following treatment of HeLa cells with CHX or Rocaglamide 
A (RocA, 100 nM). (B) A mitochondrial-targeted ATP FRET biosensor (Mit-ATEAM) 
was used to determine mtATP levels in HeLa cells treated with the protein synthesis 
inhibitor Rocaglamide A. TXNIP mRNA levels in HeLa cells treated with CHX and (C) 
TXNIP mRNA levels following CHX treatment of HeLa cells with siSCRM or siATP5I.  
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Figure 3.10. TXNIP is a key feature of cytotoxicity elicited by protein synthesis 
inhibition 
HeLa cells treated with siEIF4E and the impact on (A) TXNIP mRNA and (B) protein 
levels. Immunoblot showing TXNIP protein levels following RocA treatment of (C) 
HeLa cells and (D) the triple-negative breast cancer cell lines MDA-MB-157 and MDA-
MB-231. (E) MDA-MB-157 cells were generated to express control scrambled shRNA 
(shScrm) or shTXNIP. Cells were then treated with RocA for two days following which 
cell viability was analyzed by crystal violet. 
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Figure 3.11. Supplement: Protein synthesis inhibition restricts glucose uptake. 




Figure 3.12. Supplement: TXNIP is a key feature of cytotoxicity elicited by protein 
synthesis inhibition. 
TXNIP+/+ or TXNIP-/- MEFS were treated with RocA for two days then cell viability was 

















Figure 3.13. Protein synthesis inhibitors initiate a MondoA/TXNIP-dependent stress 
response. 
(A) Immunoblot of HeLa cells in which MondoA and TXNIP have been knocked out 
using CRISPR/Cas9. (B) RNA-sequencing was conducted for HeLa, HeLa:MondoA-KO 
and HeLa:TXNIP-KO cells treated with RocA. Shown above is a venn-diagram 
indicating overlap in differentially regulated genes (log2(fold change) of at least 2). Of 
note, MondoA and TXNIP are necessary for about 11% and 25% of gene expression 
induced by RocA respectively. Plots showing log2FC for HeLa cells compared to (C) 
log2FC for HeLa:MondoA-KO cells and (D) log2FC for HeLa:TXNIP-KO cells. TXNIP, 
ARRDC4 and RRAD are indicated. (E) Data tracks showing the aligned reads for RRAD 
in HeLa, HeLa:MondoA-KO and HeLa:TXNIP-KO cells treated with DMSO or RocA. 
(F) Schematic depicting the effects of protein synthesis on mitochondria metabolism and 
MondoA activity. During protein synthesis inhibition, the mitochondrial ATP is increase 
and its export from the mitochondria drives the synthesis of G6P by mitochondria-linked 
hexokinase. G6P signals to MondoA to translocate to the nucleus and drive expression of 
TXNIP and other stress-responsive genes. 
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MondoA is a basic helix-loop-helix leucine zipper (bHLH-Zip) transcription 
factor that drives expression of thioredoxin-interacting protein (TXNIP). We recently 
demonstrated that Myc is a transcriptional repressor of TXNIP expression, and that Myc 
and MondoA compete for a binding site in the TXNIP promoter. While Myc-dependent 
transcription has been well-studied, little is known about the full complement of genes 
regulated by MondoA. Further, it is known that TXNIP can play a role in transcription, 
yet specific genes that TXNIP regulates are unknown. Here we use CRISPR/Cas9 editing 
and next-generation sequencing to address these questions. We observed significant 
overlap in the genes that are differentially regulated by MondoA and TXNIP, therefore, 
we suggest that MondoA requires TXNIP for its transcriptional activity. We show that 
Myc/MondoA competition extends to thousands of sites across the genome, and 
specifically characterize the reciprocal regulation of electron transport chain biogenesis. 
During Myc overexpression, loss of MondoA sensitized cells to apoptosis. Thus, by 
antagonizing Myc transcriptional activity, MondoA acts as a safeguard against Myc-
driven cell death. 
4.2. Introduction 
MondoA is a bHLH-Zip transcription factor that senses and controls metabolic 
states of the cell. Mechanistically, MondoA senses high levels of glucose-6-phosphate 
(G6P) and responds by translocating to the nucleus where it controls transcription of 
genes involved in nutrient homeostasis. The most well-characterized MondoA target gene 
is thioredoxin-interacting protein (TXNIP), a negative regulator of glucose uptake. Thus, 
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MondoA and TXNIP form an axis that senses and regulates glucose uptake. 
 We previously showed that in triple-negative breast cancer (TNBC) Myc-drives 
aerobic glycolysis at least in part by suppressing TXNIP expression. MondoA and Myc 
compete for a binding site in the TXNIP promoter and thus, differentially regulate its 
expression (Shen et al., 2015). Consistent with our findings in TNBC, Myc/MondoA 
antagonism also occurs in BRAFV600E melanomas (Parmenter et al., 2014). However, in 
neuroblastoma and Myc-overexpressing B-cell leukemia, Myc and MondoA cooperate to 
drive expression of target genes (Carroll et al., 2015). Further studies are needed to 
determine the mechanisms by which MondoA and Myc compete and cooperate. 
Little is known about the other genes that MondoA regulates. TXNIP expression 
is highly, if not entirely dependent on MondoA in nearly all extra-hepatic tissues, yet 
other MondoA target genes are not as straightforward. Other MondoA-regulated genes 
are appear to be context specific. For example, while in kidney epithelial (HA1ER) cells, 
MondoA downregulates MYC (Stoltzman et al., 2008), in triple-negative breast cancer, 
MondoA doesn’t have any apparent control over MYC expression (Figure 4.1A). 
Identifying a common set of MondoA-regulated genes will provide new insight into how 
Myc and MondoA coordinate the use and availability of nutrients.  
 We used CRISPR/Cas9 to generate clonal TNBC cell lines that had loss of 
MondoA or TXNIP expression. Using mRNA-sequencing, we determined that MondoA 
and TXNIP loss results in similar transcriptional profiles. We propose that MondoA 
requires TXNIP for its transcriptional activity. Additionally, we observed that MondoA 
loss led to increased Myc-dependent transcription and increased sensitivity to cells to 
Myc-driven cell death. We conducted a complete evaluation of the sites in the genome 
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that MondoA binds in quiescence and in the G1 phase of the cell cycle. We observed 
reciprocal binding of Myc and MondoA at the same sites during G0 and G1. Our findings 




 We generated cell lines that did lack expression of MondoA and TXNIP using 
CRISPR/Cas9 editing. In short, for each gene we coexpressed CRISPR/Cas9 and three 
sgRNAs (from the GeCKO v2 library). The CRISPR/Cas9 plasmid also contained GFP 
as a marker for transfection efficiency. We used fluorescence-assisted sorting to collect 
cells with the highest GFP expression. Cell clones were derived from single cells and 
screened for expression of MondoA and TXNIP using RT-qPCR and immunoblotting. 
We identified multiple clonal colonies that did not express MondoA or TXNIP (Figure 
4.1A). As expected, loss of MondoA abolished TXNIP expression illustrating the 
necessity of MondoA for TXNIP expression (Stoltzman et al., 2008). 
 
4.3.1. MondoA transcriptional activity requires TXNIP 
 In order to determine the consequence of MondoA and TXNIP loss on 
transcription, we conducted mRNA-sequencing on three clones for each knock-out type 
(231:MondoA-KO and 231:TXNIP-KO). We used principal component analysis to 
predict transcriptional variation for each clone. Both 231:MondoA-KO and 231:TXNIP-
KO clones clustered away from parental MDA-MB-231 cells (Figure 4.1B). 231:TXNIP-
KO clones 1 and 3 clustered with all three 231:MondoA-KO clones, suggesting that the 
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transcriptional profiles may be similar. We observed very little variance among two 
biological replicates of MDA-MB-231, demonstrating the fitness of the mRNA-
sequencing data. 
We next used DESeq2 to quantify expression as fragments per kilobase of 
transcript per million mapped reads (FPKM) and fold changes relative to MDA-MB-231. 
Using a threshold of log2(fold change) ≥ 1, we identified 1256 and 1139 genes that were 
differentially regulated in 231:MondoA-KO and 231:TXNIP-KO clones, respectively, of 
which 844 were differentially regulated in both cell types (Figures 4.1C-E). Notably, we 
only considered genes that had an adjusted p-value of at least 20. We used RT-qPCR to 
validate the differential expression of several genes (data not shown). 
We next performed Gene Set Enrichment Analysis (GSEA) using gene sets 
derived from differentially regulated genes from either 231:MondoA-KO or 231:TXNIP-
KO cells. 231:MondoA-KO cells showed enrichment for both TXNIP upregulated and 
downregulated genes (Figure 4.1F). Similarly, 231:TXNIP-KO cells showed enrichment 
for both MondoA upregulated and downregulated genes (Figure 4.1G). Further, the 
degree to which genes are regulated in 231:MondoA-KO and 231:TXNIP-KO cells is 
similar (Figure 4.1H). Finally, we also observed significant overlap in differentially 
regulated genes from HeLa cells with loss of MondoA or TXNIP (Figure 4.1I). Together 
these findings indicate that loss of MondoA or TXNIP leads to highly similar gene 
expression profiles. 
The high degree of similarity in gene expression between the 231:MondoA-KO 
and 231:TXNIP-KO led us to hypothesize that TXNIP positively regulates MondoA 
transcriptional activity. To address this model, we expressed exogenous TXNIP in 
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231:MondoA-KO1 and 231:TXNIP-KO1 cells (Figure 4.2A). In 231:MondoA-KO cells, 
exogenous expression of TXNIP had no effect on the expression of FOXA2, PGF and 
INHBB, indicating that TXNIP alone is not sufficient to regulate these genes (Figures 
4.2B-4.2D). However, when TXNIP was expressed in 231:TXNIP-KO, we observed a 
restoration of FOXA2, PGF and INHBB expression. These results demonstrate that both 
MondoA and TXNIP are necessary for the regulation of a set of genes, and that TXNIP 
alone is not sufficient to control these genes. This suggests that MondoA and TXNIP 
cooperate in transcriptional regulation. This is consistent with the findings of Chen et al. 
showing that TXNIP regulates its own expression (Chen et al., 2014). Preliminary data 
from our lab suggests that TXNIP is necessary for nucleocytoplasmic shuttling of 
MondoA (data not shown). Because glucose controls the nucleocytoplasmic shuttling of 
MondoA, we propose that TXNIP plays a role in the nutrient-sensing by MondoA. A 
model that might explain this finding is that as TXNIP is downregulated, cells undergo a 
shift from oxidative metabolism to aerobic glycolysis. This results in decreased mtATP 
production, thus restricting MondoA transcriptional activity (Figure 4.2E). 
4.3.2. MondoA and Myc antagonism 
We recently showed that Myc is a transcriptional repressor of TXNIP, likely by 
competing with MondoA for a shared binding site in the TXNIP promoter (Shen et al., 
2015). We sought to identify other genes that Myc and MondoA regulate 
antagonistically. We therefore analyzed our mRNA-sequencing data to determine how 
MondoA loss affects Myc-dependent transcription. We used GSEA to compare our 
mRNA-sequencing data to Myc target genes. Using the 231:MondoA-KO dataset, we 
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observed enrichment for Myc upregulated and downregulated genes (Figure 4.3A), 
suggesting that Myc transcription activity was enhanced at both upregulated and 
downregulated genes. Consistent with our findings showing that MondoA requires 
TXNIP (Chapter 4.3.1), 231:TXNIP-KO cells are also enriched for Myc regulated gene 
expression (Figure 4.3B). Using the differentially regulated genes identified in the 
analyses described above, we generated MondoA and TXNIP gene sets. These gene sets 
included the top 100 upregulated and downregulated genes for each genotype. We then 
compared the gene sets to multiple Myc-overexpression datasets obtained from GEO 
(GSE5823; Cappellen et al., 2007). Myc overexpression in MDA-MB-231, MCF7 and 
HeLa cells led to enrichment of MondoA and TXNIP regulated genes (Figures 4.3C and 
4.3D and data not shown). Collectively these results demonstrate the opposing regulation 
of gene expression by MondoA and Myc (Figures 4.3E). 
We next determined genome occupancy for Myc and MondoA during quiescence 
(G0) and the G1 phase of the cell cycle. Previously, we showed that MondoA 
transcriptional activity is high during G0 and low during G1, and conversely Myc 
expression and transcriptional activity is low during G0 and high during G1 (Elgort et al., 
2010; Shen et al., 2015). We starved MDA-MB-231 cells of serum for 72 hours to ensure 
all cells entered G0. Serum was added back to some of the samples, and six hours later 
cells were harvested and chromatin-immunoprecipitation sequencing (ChIP-sequencing) 
was used to determine the genome occupancy of MondoA, Myc and PolII. Antibodies 
against endogenous MondoA, Myc and Polymerase II (PolII) were used to pulldown 
transcription factor/DNA complexes. DNA was purified, processed for sequencing, 
amplified and processed on an Illumina HiSeq 50. Sequencing reads were aligned to 
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genomic build hg19. Reads were normalized to input DNA and peaks were identified 
using MACS2. Peaks were identified using from the G0 MondoA ChIP and the G0 Myc 
ChIP, which we called “MondoA-bound” and “Myc-bound” regions, respectively. We 
identified significantly more Myc-bound regions than MondoA-bound regions (Figures 
4.4 and 4.5); however, we recognized that MondoA is enriched at Myc-bound regions, 
but to a lesser extent. For both Myc-bound and MondoA-bound regions, Myc binding 
was increased during G1 and decreased during G0. Conversely, MondoA binding was 
increased during G0 and decreased during G1. We identified several regions where 
MondoA and Myc were both enriched, which we called “cobound regions.” Meme 
analysis by John O’Shea showed enrichment for ChoRE-like sequences at the cobound 
regions (data not shown). This reciprocal binding by MondoA and Myc is further 
evidence that MondoA and Myc competitively regulate the same genes. 
We next sought to characterize Myc/MondoA antagonism in a biological 
pathway. Myc is a master regulator of mitochondrial and ETC biogenesis (Dang, 2013; 
Li et al., 2005). Given that MondoA and Myc control many of the same genes, we 
hypothesized that MondoA also regulates ETC biogenesis. We conducted GSEA using 
mRNA-sequencing data from above, and observed increased expression of ETC genes in 
231:MondoA-KO cells (Figure 4.6A). We used RT-qPCR to verify the results of the 
mRNA-sequencing (Figure 4.6B). Using the ChIP-sequencing data described above, we 
determined whether MondoA binds to ETC gene promoters. We observed enrichment for 
both MondoA and Myc on ETC gene promoters, suggesting that MondoA is a direct 
negative-regulator of ETC biogenesis (Figure 4.6C). Finally, we extended these findings 
to another cell type. We used gene expression data obtained from HeLa:MondoA-KO 
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cells (described in Chapters 2 and 3) and found that loss of MondoA in HeLa cells also 
lead to an enrichment of ETC genes (Figure 4.6D). These data suggest that Myc and 
MondoA competitively regulate ETC biogenesis. 
Finally, we sought to determine the biological impact of Myc/MondoA 
antagonism. While the oncogenic effects of Myc are to drive cell growth and 
proliferation, in certain circumstances Myc overexpression drives cell death (Cermelli et 
al., 2014; Evan and Littlewood, 1998; Evan et al., 1992). Because it stimulates 
biosynthetic pathways, Myc innately drives metabolic stress by depleting nutrients. Myc 
requires other adaptions to counter the metabolic stress and support cell survival. When 
one or more of those adaptations are lost, the cell undergoes Myc-driven apoptosis (Myc 
synthetic lethality; Figure 4.7A). Yet loss of some adaptations only sensitizes cells to 
Myc synthetic lethality. One adaptation to high Myc activity is to activate transcription 
factors that target the same genes as Myc. For example, Mnt regulates Myc target genes 
in the opposite direction of Myc, and loss of Mnt leads to Myc synthetic lethality (Link et 
al., 2012).  We therefore hypothesized that MondoA loss sensitizes cells to Myc-driven 
cell death. Further, we reasoned that synthetic lethality would be more evident as Myc 
levels and transcriptional activity increased (Figure 4.7B). 
In order to test this hypothesis, we expressed Myc fused to estrogen-receptor (ER-
Myc) in MDA-MB-231, 231:MondoA-KO and 231:TXNIP-KO cells. ER-Myc is 
constitutively cytoplasmic, yet when cells are treated with 4-hydroxytamoxifin (4OHT), 
ER-Myc translocates to the nucleus and is transcriptionally active (Figure 4.7C). Using a 
cell proliferation assay, we determined the response to 4OHT treatment relative to 
nontreated cells. We observed a decrease in 231:MondoA-KO cell viability compared to 
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MDA-MB-231 cells (Figure 4.7D). This suggests that MondoA is critical for cells to 
adapt to high Myc levels. The specific target genes MondoA that regulates to counter 
Myc synthetic lethality remains to be investigated. Further, it will be important to 
determine whether this result extend to other cell types. ER-Myc does not restrict cell 
viability in 231:TXNIP-KO cells as it does in 231:MondoA-KO cells (Figure 4.7D). 
While the gene expression profiles of 231:MondoA-KO and 231:TXNIP-KO cells are 
highly similar, this result illustrates the importance of nonoverlapping functions of the 
two cell types. 
4.3.3. MondoA and TXNIP in tumorigenesis 
Our gene expression and genome occupancy data suggest that MondoA and 
TXNIP act as tumor suppressors in TNBC. We sought to verify this idea using in vivo 
tumor growth assays. We injected MDA-MB-231, 231:MondoA-KO and 231:TXNIP-KO 
cells into the cleared mammary fat pad in NOD/SCID mice (Figure 4.8A). We tracked 
tumor growth over the next several weeks, then harvested tumors and analyzed for size 
and morphology. Surprisingly, loss of MondoA or TXNIP led to significant decreases in 
tumor size (Figure 4.8B). 
We next determined how gene expression contributes to this decrease in tumor 
size. We therefore conducted mRNA-sequencing on MDA-MB-231, 231:MondoA-KO 
and 231:TXNIP-KO tumors. After aligning reads to the genome, we used DESeq2 to 
determine the differentially regulated genes. In this analysis, we also included MDA-MB-
231, 231:MondoA-KO and 231:TXNIP-KO samples from tissue culture (Chapter 4.3.1). 
Hierarchical clustering and principle component analysis showed that MDA-MB-231 
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deviated from 231:MondoA-KO and 231:TXNIP-KO to a much greater extent in the 
tumors than in cell culture (Figures 4.9A and 4.9B). Consistent with this finding using a 
cutoff of log2(fold-change) ≥ 0.585, we observed about a three-fold increase in the 
number of differentially regulated genes in the 231:MondoA-KO and 231:TXNIP-KO 
relative to MDA-MB-231 tumor samples (data not shown). Consistent with what we 
observed in tissue culture, tumors derived from 231:MondoA-KO and 231:TXNIP-KO 
cells had similar transcriptional profiles (Figures 4.9A and 4.9B and data not shown). We 
conducted pathway analysis on the genes that are differentially regulated in tumors after 
MondoA loss. There was a significant enrichment for pathways involving interferon 
signaling, HDAC1/HDAC2 function and KRAS activity (Figure 4.9C). Functional 
studies will be needed to determine whether dysregulation of interferon, HDACs and/or 
KRAS are responsible for the decrease in tumorigenesis.  
We compared differentially regulated genes from 231:MondoA-KO tumors, 
231:MondoA-KO cells in culture and human mammary epithelial cells expressing an 
shRNA against MondoA. Using a log (fold change) ≥ 0.585, we observed 72 genes that 
overlapped in all three groups (Figure 4.9D). We conducted pathway analysis on these 72 
genes and observed enrichment for interferon signaling, p63 activity, glutathione 
metabolism, selenium regulation, cell cycling and arachidonic acid metabolism. How 
these differentially regulated genes or pathways contribute to loss of tumorigenesis upon 




Outlined in this Chapter is the impact that loss of MondoA or TXNIP has on 
TNBC transcription and tumorigenesis. We demonstrated that MondoA and TXNIP have 
similar transcriptional profiles. Given the finding that TXNIP is essential for its own 
transcription (Chen et al., 2014), we have proposed a model in which TXNIP supports 
MondoA transcriptional activity. TXNIP loss is sufficient to drive glucose uptake and 
aerobic glycolysis (Hui et al., 2008; Kaadige et al., 2009; Wu et al., 2013). We propose 
that TXNIP deletion in MDA-MB-231 of Hela cells drives a shift from oxidative 
metabolism to aerobic glycolysis. This shift reduces levels of mtATP, which is necessary 
to activate MondoA transcriptional activity (see Chapter 2). 
Loss of MondoA or TXNIP led to increased expression of electron transport chain 
(ETC) and mRNA translation genes and decreased expression of genes involved in 
MAPK and VEGF signaling (Figure 4.1E). These findings were consistent with 
published reports showing that VEGF signaling requires TXNIP (Abdelsaid et al., 2013); 
MAPK signaling requires TXNIP (Ren et al., 2010); and TXNIP is necessary for proper 
control of mitochondrial metabolism and oxidative phosphorylation (DeBalsi et al., 
2014). The MondoA/TXNIP axis is controlled by ETC (Chapter 2), mRNA translation 
(Chapter 3), and MAPK signaling (Elgort et al., 2010), leading us to propose that the 
MondoA/TXNIP axis is involved in feedback regulation of these diverse processes. ETC 
gene upregulation is also paradoxical with the increase in glucose uptake and aerobic 
glycolysis observed when MondoA and TXNIP are lost (Hui et al., 2008; Kaadige et al., 
2009; Wu et al., 2013). We propose that the upregulation of ETC genes is required to 
accommodate the increased glucose uptake and metabolism. 
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We also expanded our understanding of Myc/MondoA antagonism by showing 
that it occurs at hundreds of genes. We demonstrated that Myc and MondoA compete in 
the regulation of ETC biogenesis. Conceptually, because the MondoA/TXNIP axis senses 
mitochondrial ATP (see Chapters 2 and 3) the negative regulation of ETC biogenesis by 
MondoA, establishes a negative feedback loop. As carbons enter the TCA cycle and fuel 
ETC-mediated ATP synthesis, MondoA becomes transcriptionally active and 1) restricts 
glucose uptake and flux of carbons into mitochondrial metabolism driving expression of 
TXNIP, and 2) directly downregulate nuclear-encoded ETC genes. Finally, we showed 
that in conditions where Myc is overexpressed, MondoA is necessary to counter Myc-
driven apoptosis, indicating an essential role for MondoA in Myc-driven tumorigenesis. 
This is consistent with our reports demonstrating that in some cancers Myc and MondoA 
antagonistically regulate the same genes, and that in tumors with high Myc expression, 
loss of MondoA leads to synthetic lethality (Carroll et al., 2015) Parmenter et al., 2014; 
Shen et al., 2015; Wilde and Ayer, 2015). 
The ChIP-sequencing data showed Myc and MondoA bind the same regions in 
the genome in a mutually exclusive manner. Of note, for the MondoA peaks, PolII 
binding was offset from the MondoA/Myc binding site about 150 bp, approximately the 
size of one nucleosome (Figure 4.5). This result has led us to hypothesize that MondoA 
might act as a pioneer factor, binding to chromatin-rich regions and recruiting factors that 
open/close chromatin. Yet how MondoA binds and its molecular functions at these 





4.5. Experimental procedures 
4.5.1. Cell culture 
MDA-MB-231 cells and its derivative lines were incubated at 37 ºC in 5% CO2. 
Cells were passaged in DMEM (Gibco) with penicillin/streptomycin (Gibco), 10% FBS 
(Gibco) and 1% non-essential amino acids (Gibco) using standard cell culture practices. 
 
4.5.2. mRNA-sequencing 
Total RNA was extracted from cells using a Quick RNA Miniprep Kit (Zymo 
Research) according to manufacturer’s recommendations. mRNA was isolated and 
library production performed using a Stranded mRNA-Seq Kit with mRNA Capture 
Beads (Kapa). Library quality was analyzed using an Agilent High Sensitivity D1000 
ScreenTape. Single-end sequencing for 50 cycles was performed using an Illumina 
HiSeq. 
 
4.5.3. Chromatin-immunoprecipitation sequencing 
Chromatin-immunoprecipitation was performed as described previously (Shen et 
al., 2015). Library preparation was described as described previously (Carleton et al., 
2017). 
 
4.5.4. Bioinformatic analysis 
Reads were aligned to hg19 using Novoalign. DESeq2 was used to determine the 
number of fragments for each gene, compute a value for fragments per kilobase of the 
gene per million fragments read (FPKM), determine R-log transformations, calculate 
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log2(fold change) for each gene, and determine an adjusted p-value. Hierarchical 
clustering was performed using sample-distance matrices computed by DESeq2. 
Principle component analysis was performed for the R-log values using the R package. 
Gene Set Enrichment Analysis (GSEA) was conducted using the Broad Institute’s 
publically available GSEA application. FPKM values were compared to published and 
unpublished gene sets. ConsensusPathDB (Max Planck Institute for Molecular Genetics) 
was used to conduct overrepresentation analysis on differentially regulated genes 
(Herwig et al., 2016; Kamburov et al., 2013). For ChIP-sequencing, MACS2 was used to 
identify bound regions, and DeepTools was used to visualize the data. 
4.5.5. Orthotopic xenografts 
All animal procedures were reviewed and approved by the University of Utah 
Institutional Animal Care and Use Committee. 100,000 cells (in 100 µl matrigel) were 
implanted into the cleared right inguinal mammary fat pad of NOD/SCID mice between 3 
and 6 weeks old. Mice were calipered for tumor growth until the largest tumor (MDA-
MB-231) reached 2 cm3, at which time all mice in the study were euthanized and 
analyzed for tumors. Tumor weight was analyzed relative to brain weight. 
4.5.6. Reverse transcriptase quantitative PCR 
Total RNA was extracted from cells using the RNAeasy Kit (Qiagen). cDNA was 
synthesized from 200 ng RNA using GoScript reverse transcription kit (Promega). cDNA 
was diluted 10-fold and qPCR was performed using OneTaq Hot Start DNA Polymerase 
(Heidelberger et al., 1957), SYBR/ROX Combo PCR DNA Fluorescence Dye (Thermo 
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Fisher) and dNTPs (Thermo Fisher). 
 
4.5.7. Immunoblotting 
 Immunoblotting was performed as described previously (Kaadige et al., 2015). 
Primary antibodies were used at a dilution of 1:1000 anti-MLXIP (Proteintech, 13614-1-
AP), 1:1000 anti-TXNIP (Abcam, ab188865), and 1:15,000 anti-Tubulin (Molecular 
Probes, 236-10501). 
 
4.5.8. Cell viability/proliferation 
Cells were stained using crystal violet staining solution (0.05% crystal violet, 1% 
formaldehyde and 1% methanol in PBS). Plates were rocked gently at room temperature 
for one hour. Staining solution was then aspirated and water was used to wash wells 
several times. 1% SDS in water was used to solubilize crystal violet and relative amount 
of solubilized crystal violet was determined by measuring absorbance at 590 nm. 
 
4.5.9. Statistical methods 
Significance was determined using a two-tailed student’s t-test. Where applicable, 
one-way or two-way ANOVA was performed prior to determining significance. 
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Figure 4.1. MondoA and TXNIP regulated genes 
(A) CRISPR/Cas9 was used to generate clonal cell lines with MondoA or TXNIP loss.
Immunoblot showing MondoA and TXNIP loss in MDA-MB-231, 231:MondoA-KO and
231:TXNIP-KO cells. (B) mRNA-sequencing was performed on parental cells and
MondoA and TXNIP knockout clones. Principle component analysis showing variance
among clonal colonies and parental cells. Log2(fold changes) for several genes in (C)
231:MondoA-KO and (D) 231:TXNIP-KO cells. (E) Venn diagram indicating significant
overlap in differentially regulated genes in 231:MondoA-KO and 231:TXNIP-KO cells.
Two venn diagrams are depicted for genes upregulated in the knockout clones and genes
downregulated in the knockout clones. GSEA was performed using (F) 231:MondoA-KO
and (G) 231:TXNIP-KO datasets and comparing TXNIP- and MondoA-regulated genes
sets, respectively. (H) Log2(fold-change) in gene expression for 231:MondoA-KO cells
compared to 231:TXNIP-KO cells. (I) Venn diagram indicating significant overlap in




Figure 4.2. MondoA requires TXNIP 
Exogenous TXNIP was expressed in 231:MondoA-KO and 231:TXNIP-KO cells. mRNA 
levels were determined for the MondoA/TXNIP target genes, (A) TXNIP, (B) PGF, (C) 
INHBB and (D) FOXA2. (E) Depiction of our model that supports MondoA 
transcriptional activity. Loss of TXNIP causes a shift from oxidative metabolism to 





Figure 4.3. MondoA loss leads to Myc transcriptional activity 
GSEA was performed using (A) 231:MondoA-KO and (B) 231:TXNIP-KO datasets and 
comparing Myc transcriptional regulation gene sets. GSEA was performed using (C) 
MondoA-regulated and (D) TXNIP-regulated gene sets compared to datasets from Myc 
overexpressing HeLa, MCF7 and MDA-MB-231 cells. (E) Schematic depicting 
Myc/MondoA antagonism. 
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Figure 4.4. Myc and MondoA bind the same regions in the genome 
ChIP-sequencing was performed on MDA-MB-231 cells in quiescence (-serum) or in the 
G1 phase of the cell cycle (+serum). The heatmaps shown are a depiction of abundance 
of MondoA (orange), Myc (blue) and PolII (green) at binding sites across the genome. 
The sites selected are based on enrichment over an input sample. Myc-bound genes (top) 
are the sites that were identified from the Myc-IP, +serum sample. MondoA-bound genes 
(bottom) are the sites that were identified from the MondoA-IP, -serum sample.
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Figure 4.5. Myc and MondoA bind the same regions in the genome 
ChIP-sequencing was performed on MDA-MB-231 cells in quiescence (-serum) or in the 
G1 phase of the cell cycle (+serum). The heatmaps shown are a depiction of abundance 
of MondoA (orange), Myc (blue) and PolII (green) at binding sites across the genome. 




Figure 4.6. MondoA and Myc competitively regulate ETC biogenesis 
(A) GSEA conducted for 231:MondoA-KO cell mRNA-sequencing data compared to the 
gene set, 
REACTOME_RESPIRATORY_TRANSPORT_CHEMOSMOTIC_COUPLING_AND_ 
HEAT_PRODUCTION. (B) RT-qPCR for nuclear-encoded ETC genes in HeLa (black 
bars) and HeLa:MondoA-KO (colored bars) cells. Significantly regulated genes are 
indicated with asterisks. (C) Heatmaps shown are a depiction of abundance of MondoA 
(orange), Myc (blue) and PolII (green) at the promoters of nuclear-encoded ETC genes. 
(D) GSEA conducted for HeLa:MondoA-KO cell mRNA-sequencing data (Chapters 2 
and 3) compared to the gene set, 
REACTOME_RESPIRATORY_TRANSPORT_CHEMOSMOTIC_COUPLING_AND_




Figure 4.7. Myc synthetic lethality in MondoA-KO cells 
(A) Depiction of the general concept of Myc synthetic lethality. Myc has several factors 
such as nutrients and growth factors that prevent Myc-driven apoptosis. When one or 
more of these factors are lost, the cells experience Myc-driven cell death. (B) Our model 
of MondoA in Myc synthetic lethality. We propose that as Myc levels increase, MondoA 
is required more to counter Myc transcriptional activity and Myc-driven cell death. (C) 
Depiction of how ER-Myc occurs. Briefly, ER-Myc is cytoplasmic, yet when cells are 
treated with 4-hydroxytamoxifin (4OHT), ER-Myc translocates to the nucleus and drives 
transcription. (D) Cell viability assay conducted after ER-Myc activation by 4OHT 





Figure 4.8. Orthotopic xenograft 
(A) Depiction of experiment. Cells were implanted into cleared mammary fat pads. (B) 
Tumor to brain weight ratio was determined at the end of the experiment. 
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Figure 4.9. MondoA and TXNIP regulated gene expression in vivo 
mRNA-sequencing was performed on tumor tissues derived from MDA-MB-231, 
231:MondoA-KO and 231:TXNIP-KO cells. (A) Hierarchical clustering depicts how 
similar/dissimilar samples are from other samples. (B) Principle component analysis was 
performed to determine the level of variation in the samples. (C) Overrepresentation 
analysis was conducted using ConsensusPathDB. Shown here are the top most regulated 
pathways in response to MondoA loss. (D) Differentially regulated genes were compared 
to the differentially regulated genes for two other datasets: 231:MondoA-KO in cell 

















The ability to sense nutrients and respond to maintain metabolic homeostasis is a 
central tenet of biology. Glucose is a fundamental nutrient for constructing and fueling 
cells. Controlling glucose availability is necessary for establishing proper metabolic 
states. The MondoA/TXNIP axis is a nexus of cellular glucose homeostasis. The 
MondoA transcription factor senses glucose availability and drives expression of its 
target gene thioredoxin-interacting protein (TXNIP), a negative regulator of glucose 
uptake. Thus, the MondoA/TXNIP axis controls glucose homeostasis. Dysregulation of 
the MondoA/TXNIP axis underlies a number of metabolic diseases including diabetes 
and cancer. In this dissertation, we explored the molecular mechanisms that trigger the 
MondoA/TXNIP axis as well MondoA-dependent transcriptional outputs. 
MondoA resides on the outer mitochondrial membrane (OMM) (Sans et al., 
2006). Our previous work demonstrated that MondoA senses glucose-6-phosphate (G6P) 
and responds by translocating to the nucleus and driving transcription (Stoltzman et al., 
2008). MondoA also requires a signal from the electron transport chain (ETC) to become 
transcriptionally active, yet the identity of the ETC signal has remained unclear (Yu et 
al., 2010). By monitoring both glycolytic flux and oxidative phosphorylation, MondoA is 
centrally situated to be a master regulator of central carbon metabolism. The primary goal 
of this project was to identify the metabolic determinants of MondoA transcriptional 
activity. 
In Chapter 2, we demonstrate that acidosis drives MondoA-dependent TXNIP 
expression. Treatment with low pH medium leads to intracellular acidification. 
Intracellular pH is a strong determinant of glycolytic flux and acidification leads to 
decreased glucose uptake (Gunnink et al., 2014; Webb et al., 2011). This finding led us to 
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investigate the molecular mechanisms by which acidosis triggers the MondoA/TXNIP 
axis. Acidosis treatment leads to hyperpolarization of the inner-mitochondrial membrane, 
which is sufficient to drive mitochondrial-ATP (mtATP) synthesis. Our results 
demonstrate that mtATP is a necessary signal for MondoA transcriptional activity. As 
mtATP is exported from the mitochondrial matrix, it is consumed by hexokinase to 
produce G6P, a potent activator of MondoA transcriptional activity. Future work will 
focus on how G6P stimulates MondoA transcriptional activity. 
MondoA is necessary for cell proliferation under acidosis. Chapter 2 also outlined 
the MondoA-dependent transcriptional response to acidosis. MondoA is responsible for 
about 50% of acidosis-driven transcription. Among the pathways that MondoA regulates 
in response to acidosis is cholesterol biosynthesis. Given that cholesterol protects against 
acidosis-mediated membrane damage, we propose that MondoA drives a cell protective 
response to acidosis, of which cholesterol biosynthesis is a key feature (Zhou et al., 
2009). 
Results presented in Chapter 2 show that MondoA integrates signals from both 
glycolysis, and oxidative phosphorylation, to exert control over nutrient homeostasis. 
Given that MondoA, Mlx and hexokinase all localize to the OMM, we propose that they 
are part of a signaling center that senses and controls central carbon metabolism. 
Tethering signaling complexes to membranes is a common theme in biology. For 
example, the mTORC1/Ragulator complex is tethered to the lysosome where it senses 
nutrients from the lysosomal lumen and the cytosol (Saxton and Sabatini, 2017). 
In Chapter 3 we demonstrate that protein synthesis inhibitors trigger the 
MondoA/TXNIP axis. Protein synthesis inhibition leads to significant metabolic rewiring 
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and increased production of mtATP. As was shown in Chapter 2, MondoA senses this 
increase in mtATP through the generation of G6P by mitochondria-bound hexokinase. 
Protein synthesis inhibitors likely enhance TCA cycle flux to drive ETC-mediated 
production of mtATP production. Thus, in the context of protein synthesis inhibition, the 
MondoA/TXNIP axis is also linked to mtATP production. 
Protein synthesis inhibitors have been proposed as potential therapeutics for 
various cancers. Rocaglamide A (RocA) is an translation initiation inhibitor that drives 
apoptosis in a number of cancer types. RocA drives a robust increase in TXNIP 
expression and a reduction in glucose uptake. The induction of TXNIP is essential for full 
RocA-mediated growth suppression, suggesting a role for TXNIP in protecting against 
protein synthesis inhibition. 
Chapter 3 concludes with analysis of the RocA-stimulated MondoA-dependent 
transcriptome. TXNIP and ARRDC4 are highly induced by RocA treatment and are 
almost entirely dependent on MondoA. We identified Ras-related Associated with 
Diabetes (RRAD) as a novel target of the MondoA/TXNIP axis. RRAD is a negative 
regulator of glycolysis, thus expanding our knowledge of the potential mechanisms by 
which the MondoA/TXNIP axis restricts glycolysis. 
In Chapter 4, we determine the transcriptional consequences of MondoA and 
TXNIP loss in triple-negative breast cancer (TNBC). We made three key observations: 1) 
MondoA requires TXNIP for its transcriptional activity, 2) loss of MondoA or TXNIP 
results in increased Myc transcriptional activity, 3) loss of MondoA sensitizes cells to 
Myc-driven cell death, and 4) MondoA and TXNIP loss has a much greater impact on 
transcription in tumors compared to cells in culture. 
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We first demonstrate that TNBC cell lacking MondoA and TXNIP have a similar 
transcriptional profile. Importantly, TXNIP expression is highly, if not entirely, 
dependent on MondoA transcriptional activity. Yet, TXNIP is not sufficient to rescue 
gene expression in the context of MondoA-loss. We therefore propose that the 
transcriptional activity of MondoA is dependent on TXNIP. This is consistent with the 
results of other labs showing that TXNIP drives its own transcription in a positive-
feedback loop (Chen et al., 2014). A potential model is that TXNIP loss causes a shift 
from oxidative metabolism to aerobic glycolysis. This causes a decrease in mtATP 
production, thus limiting MondoA transcriptional activity. 
Second, MondoA and TXNIP loss led to increased Myc transcriptional activity. 
Loss of MondoA or TXNIP in TNBC cells results in enrichment of genes that are directly 
regulated by Myc. In addition to driving differential gene expression, Myc and MondoA 
antagonistically bind the same sites in the genome. Further, loss of MondoA sensitizes 
cells to Myc-driven cell death. This is consistent with observations in neuroblastoma and 
Myc-amplified B-cell leukemia in which MondoA loss led to Myc-driven cell death 
(Carroll et al., 2015). 
Finally, in orthotopic TNBC xenografts, MondoA and TXNIP loss led to far more 
differentially regulated genes than cells growth in culture. This suggests that MondoA 
and TXNIP more broadly regulate transcription in vivo. Future studies will investigate 
why MondoA and TXNIP might be more transcriptionally active in tumors. A possible 
explanation is that stresses caused by the tumor microenvironment, such as acidosis, 
trigger the MondoA/TXNIP axis, resulting in increased transcription. 
The work presented here shows in multiple contexts that MondoA senses multiple 
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metabolic states. By simultaneously sensing glucose and mtATP through the production 
of G6P at the mitochondria, we recognize the following: 1) Not all pools of ATP are 
equal. mtATP pools specifically trigger MondoA/TXNIP-dependent regulation of 
glucose uptake, 2) MondoA and hexokinase make up a signaling center on the surface of 
the mitochondria to control glucose homeostasis, and 3) MondoA is a coincidence 
detector that integrates glycolytic and mitochondrial metabolites in order to control 
nutrient homeostasis. 
How MondoA senses G6P remains to be determined. Further studies on the 
molecular mechanisms that control the MondoA/TXNIP axis and its impact on 
metabolism and cancer will provide important insights into an adaptive response to 
central carbon metabolism and ultimately aid in therapeutic approaches for cancer. 
Further, in-depth analyses of the genes regulated by MondoA will uncover biological 
consequences of MondoA-transcriptional activity.  
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Metabolic reprogramming towards aerobic glycolysis is a common feature of transformed cells and can be driven by a network of
transcription factors. It is well established that c-Myc and hypoxia-inducible factor-1a (HIF-1a) contribute to metabolic
reprogramming by driving the expression of glycolytic target genes. More recently, the c-Myc-related transcription factor
MondoA has been shown to restrict glucose uptake and aerobic glycolysis via its induction of thioredoxin-interacting protein
(TXNIP). Three recent studies demonstrate that complex and cancer type-specific interactions between c-Myc, MondoA and
HIF-1a underlie metabolism, tumourigenesis and drug response. In triple-negative breast cancer, c-Myc blocks MondoA-
dependent activation of TXNIP to stimulate aerobic glycolysis. In contrast, in neuroblastoma, N-Myc requires MondoA for
metabolic reprogramming and tumourigenesis. Finally, the therapeutic response of BRAFV600E melanoma cells to vemurafenib
requires downregulation of c-Myc and HIF-1a and upregulation of MondoA-TXNIP, and the subsequent reprogramming away
from aerobic glycolysis. In this minireview we highlight the findings in these three studies and present a working model to explain
why c-Myc and MondoA function cooperatively in some cancers and antagonistically in others.
THE PLAYERS AND THEIR ROLES
The MYC family of proto-oncogenes (c-Myc, L-Myc, N-Myc or
collectively Myc) encode basic helix-loop-helix leucine zipper
(bHLHZip) transcription factors that have roles in normal and
oncogenic physiology (Eilers and Eisenman, 2008; Meyer and
Penn, 2008). Aberrant Myc activity leads to increased cell
proliferation and growth and Myc family members are commonly
dysregulated in cancer. Cancers of many different tissue types have
dysregulated Myc and, when paired with other mutations, Myc can
drive tumourigenesis. Myc’s normal and pathological functions
have been the subject of many excellent reviews and will not be
discussed here. Rather, we focus on the interplay between Myc and
related bHLHZip factors that comprise an extended Myc network.
This extended Myc network functions to match nutrient
availability with nutrient utilisation, supporting cell growth and
tumourigenesis.
Myc requires dimerisation with another bHLHZip transcription
factor, Max, for DNA binding and the recruitment of transcrip-
tional machinery. All Myc paralogues dimerise with Max and the
different heterocomplexes have many common target genes,
although each heterocomplex has a unique subset of target genes
and expression patterns. Generally, Myc/Max complexes influence
cell growth by driving the expression genes involved in key
biosynthetic pathways and by supporting glycolysis and glutami-
nolysis (Dang, 2012b). Myc can also act as a transcriptional
repressor at certain promoters that is critical to its function in
driving cell growth and proliferation (Walz et al, 2014).
A complete functional characterisation of Myc proteins is
difficult because they do not function in isolation (O’Shea and
Ayer, 2013). Rather, their activity is potentially regulated by a
dizzying array of additional protein partnerships mediated by
families of related bHLHZip transcription factors. The first level of
regulation is mediated by the Mad family of transcriptional
repressors (Mxd1, Mxi1, Mxd3, Mxd4) that also interact with Max.
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Furthermore, Max can also interact with Mnt, which is related to
the Mad family, and Mga, which has a T-Box DNA-binding
domain in addition to its bHLHZip domain (Hurlin and Huang, 2006).
The Mxd/Max complexes repress many of the same targets that are
activated by Myc/Max complexes (Iritani et al, 2002); however, no
comprehensive genome-wide occupancy studies have been con-
ducted. The second level of regulation is mediated by a Max-like
bHLHZip protein called Mlx. Mlx can interact with Mxd1 and
Mxd4 and potentially Mnt. Mxd/Mlx, Mxd/Max and Myc/Max all
bind similar DNA sites in vitro, suggesting overlapping transcrip-
tional targets in vivo, but again no comprehensive genome-wide
study is available (O’Shea and Ayer, 2013). The third level of
regulation is that Mlx interacts with the Mondo family of
bHLHZip transcriptional activators. There are two Mondo
paralogues, MondoA (or MlxIP) and carbohydrate response
element-binding protein (ChREBP, MondoB or MlxIPL)
(Figure 1). Mondo/Mlx complexes are important nutrient sensors
and share a similar DNA-binding sequence with the rest of the
network heterocomplexes (O’Shea and Ayer, 2013). The existence
of multiple Myc-related bHLHZip factors, their assembly into
different heterocomplexes and the participation of these hetero-
complexes in potentially overlapping networks suggests that
functional output of Myc/Max complexes is likely dictated by
many mechanisms: (1) competitive or collaborative interactions
with other network complexes at shared targets, (2) competition
for limiting Max or Mlx or (3) different complexes may regulate
distinct effector pathways that compete or collaborate to control
cell growth and tumourigenesis. In this review we focus on the last
possibility as three recent papers demonstrate that Myc/Max and
MondoA/Mlx complexes play critical roles in matching the cellular
demand for nutrients with nutrient availability (Parmenter et al,
2014; Carroll et al, 2015; Shen et al, 2015).
THE MONDO FAMILY
In normal physiology, MondoA and ChREBP are ubiquitously
expressed with the highest expression in skeletal muscle and liver,
respectively, and are important regulators of glucose-dependent
transcription (Peterson and Ayer, 2011). MondoA/Mlx localise
primarily to the cytoplasm and translocate to the nucleus in
response to increased extracellular glucose concentrations. The
mechanistic details of how the heterocomplex senses extracellular
glucose are still being worked out, but current data suggest that
MondoA/Mlx complexes sense intermediates in the upper portion
of the glycolytic pathway (O’Shea and Ayer, 2013). For MondoA,
an allosteric mechanism where a glucose-derived metabolite binds
directly to the conserved N-terminus to trigger nuclear accumula-
tion, promoter binding and transcriptional activation of target
genes seems to be key (Peterson et al, 2010). The transcriptional
activity of MondoA/Mlx complexes also requires mitochondrial
electron transport (Yu et al, 2010) that enables their nuclear import
and promoter binding. Thus, MondoA/Mlx complexes sense the
status of two key bioenergetic pathways, allowing cells to adapt to
changes in glycolytic flux or mitochondrial activity.
The most well-characterised direct and glucose-dependent
target gene of MondoA/Mlx is thioredoxin-interacting protein
(TXNIP), a member of the a-arrestin family (O’Shea and Ayer,
2013). TXNIP has pleiotropic functions in different cellular stress
response pathways, with one of its most striking features being a
potent negative regulator of glucose uptake. It can suppress both
insulin-dependent and insulin-independent glucose uptake by
limiting the localisation of glucose transporters to the plasma
membrane (Wu et al, 2013). Furthermore, in some cell types
TXNIP can drive degradation of hypoxia-inducible factor-1a (HIF-
1a) (Shin et al, 2008), a central regulator of glycolytic gene
expression under hypoxic growth conditions. Thus, the glucose-
stimulated and MondoA-dependent induction of TXNIP triggers a
negative feedback loop that restricts glucose uptake until glucose
homeostasis can be restored. Furthermore, the dependence of the
MondoA/TXNIP axis on electron transport ensures that cells with
defective oxidative phosphorylation maintain a high glycolytic rate
to support cellular bioenergetics.
Given that TXNIP is a potent negative regulator of glucose
uptake and aerobic glycolysis, it is not surprising that its expression
is reduced in many cancer types and low TXNIP expression
correlates with poor clinical outcome in several cancers including
breast and gastric cancer (Shin et al, 2008; Chen et al, 2010; Shen
et al, 2015). MondoA is absolutely required for TXNIP expression,
yet MondoA is not a frequent target for mutational inactivation in
cancer. Rather, the activity of MondoA at the TXNIP promoter is
suppressed by activation of common oncogenic or pro-growth
pathways, for example Ras, PI3K and mTOR (Elgort et al, 2010;
Kaadige et al, 2015). The prevalence of Ras, PI3K and mTOR
activation across cancer types suggests broad suppression of the
MondoA/TXNIP axis in tumourigenesis.
THE EXPANDED NETWORK IN TRIPLE-NEGATIVE BREAST
CANCER
The triple-negative breast cancer (TNBC) accounts for 15–20% of
breast cancer cases. Typically, TNBCs occur earlier in life, reoccur
more frequently and have decreased overall survival. The TNBCs
lack expression of the oestrogen receptor (ER), progesterone
receptor (PR) and HER2, and hence the ‘triple-negative’ nomen-
clature (Foulkes et al, 2010). The TNBCs are more metabolic than
other breast cancer subclasses, and thus understanding how
nutrients support their growth and survival may provide pathways
for therapeutic development. Consistent with Myc’s role in
regulating aerobic glycolysis, c-Myc expression correlates with
the glycolytic phenotype of TNBCs (Palaskas et al, 2011). In
contrast, there is no general correlation between c-Myc levels or
Myc activity and glutamine utilisation or glutamine-dependence in
TNBC (Timmerman et al, 2013; Shen et al, 2015). These findings
prompted us to study how c-Myc controls glucose metabolism in













Figure 1. The extended Myc network. Transcriptional activation and
repression mediated by Myc/Max and Max/Mxd respectively drive a
transcriptional profile that coordinates nutrient utilisation.
Transcriptional activation and repression by Mondo/Mlx make up a
nutrient sensing branch of the network.






glucose uptake in multiple TNBC cell lines. Surprisingly, TXNIP
was induced in c-Myc knockdown TNBC cells and its induction
was required for the reduction in glucose uptake resulting from
c-Myc knockdown. This finding suggests that in addition to its
canonical function of driving the expression of glycolytic target
genes, c-Myc can also drive glucose metabolism by repressing
TXNIP. Mechanistically, c-Myc can bind to proximal double E-box
carbohydrate response element (ChoRE) in the TXNIP promoter,
also the known MondoA/Mlx binding site. Furthermore, TXNIP
induction following c-Myc knockdown is entirely dependent on
MondoA. Thus, either c-Myc recruits dominant transcriptional
repression machinery to the TXNIP promoter or displaces strongly
activating MondoA/Mlx complexes from the TXNIP promoter by
direct competition. MondoA levels increase at the TXNIP
promoter following c-Myc knockdown, supporting the second
model.
In the TNBC line MDA-MB-157, Myc-driven expression of
glycolytic target genes and its repression of TXNIP contribute to
Myc-driven glucose metabolism to approximately the same extent
(Shen et al, 2015). Further studies are needed to determine whether
these mechanisms are similarly balanced in other cancer types or
whether cancer type-specific mechanisms dictate their relative
contributions. Elevated c-Myc drives expression of genes that
encode many biosynthetic pathways placing a demand on
biosynthetic precursors such as glucose and glutamine (Dang,
2012a). In TNBC, c-Myc-dependent repression of TXNIP increases
glucose uptake that helps to match nutrient demand with nutrient
availability. A c-Mychigh/TXNIPlow gene signature correlates with
reduced overall survival and reduced metastasis-free survival in
breast cancer, particularly in TNBC, highlighting the clinical
significance of c-Myc-dependent repression of TXNIP (Shen et al,
2015).
It is striking that the c-Mychigh/TXNIPlow signature only
correlates with poor clinical outcome in TNBC and not in other
subtypes of breast cancer. Furthermore, the gene signature only
correlates with poor clinical outcome in tumours that also harbour
mutations in the tumour suppressor gene TP53 (Shen et al, 2015).
TP53 is mutated in between 60% and 90% of TNBCs (Turner et al,
2013), and this may explain why c-Mychigh/TXNIPlow only
correlates with poor clinical outcome in this breast cancer subtype.
Thus, there may be functional cooperation between c-Mychigh/
TXNIPlow and mutation of TP53. Importantly, this cooperation
does not appear to depend on established connections between
dysregulated c-Myc expression and TP53 mutation (Shen et al,
2015). Thus, in TNBC, c-Myc and MondoA, via their opposing
regulation of TXNIP expression, function antagonistically.
THE EXPANDED NETWORK IN BRAFV600 MELANOMA
c-Myc and MondoA antagonism also appears to be at play in
melanomas that harbour the activated alleles of the BRAF kinase
(Parmenter et al, 2014). The BRAF-mutant melanomas are highly
glycolytic and their sensitivity to the BRAF inhibitor vemurafenib
correlates with a dramatic suppression of glucose uptake and
aerobic glycolysis. Vemurafenib treatment reduces the membrane
expression of the GLUT1 and GLUT3 glucose transporters and
decreases expression of hexokinase II, the first rate-limiting
enzyme in glycolysis. Importantly, BRAFV600 melanomas rendered
resistant to vemurafenib by expression of NRASQ61K do not
reprogramme their metabolism in response to drug treatment.
Vemurafenib treatment of BRAFV600 melanomas drives upre-
gulation of TXNIP and its paralogue ARRDC4 that contributes to
its suppression of glucose uptake and aerobic glycolysis (Parmenter
et al, 2014). MondoA occupancy at the TXNIP and ARRDC4
promoters increases in response to vemurafenib treatment and this
increase is blocked by expression of NRASQ61K. As expected,
MondoA is required for upregulation of TXNIP in response to
vemurafenib. MondoA is also required for the decrease in glucose
uptake and cell proliferation driven by vemurafenib. These results
strongly implicate the MondoA/TXNIP axis as a key effector of the
vemurafenib therapeutic response.
Vemurafenib treatment also results in dramatic downregulation
of c-Myc and HIF-1a. Furthermore, functional experiments show
that downregulation of c-Myc and HIF-1a is required for
vemurafenib to suppress glucose metabolism in BRAFV600 melano-
mas. Unlike TNBCs, where c-Myc knockdown is sufficient to
upregulate TXNIP, c-Myc knockdown in one BRAFV600 melanoma
cell line only increases TXNIP slightly (Parmenter et al, 2014). Thus,
other mechanisms, in addition to c-Myc downregulation, must also
contribute to vemurafenib-dependent induction of TXNIP.
Together, these experiments establish that activation of the
MondoA/TXNIP axis along with reduction of c-Myc and HIF-1a
are required in combination for vemurafenib to reprogramme
metabolism away from glucose metabolism and suppress growth in
BRAFV600 melanomas. Given these findings, it is not surprising that
vemurafenib-treated melanomas become dependent on glutamine
(Hernandez-Davies et al, 2015). Together, these studies suggest that
c-Myc and MondoA work in opposition in these cancers.
THE EXPANDED NETWORK IN NEUROBLASTOMA
In contrast to TNBC and BRAFV600 melanomas, c-Myc and
MondoA cooperate in reprogramming metabolism and supporting
tumourigenesis in neuroblastoma (Carroll et al, 2015). Neuro-
blastoma is the most common extracranial solid tumour in
children. Approximately 20% of neuroblastomas have N-Myc
amplification that coorelates with advanced-stage disease and poor
clincal outcome (Louis and Shohet, 2015). In N-Myc-overexpres-
sing neuroblastomas, loss of MondoA or Mlx results in cell death,
demonstrating that the MondoA/Mlx heterodimer is required for
N-Myc-dependent cell growth and tumourigenesis. This finding
extends to other Myc-amplified cells including human B-cell
leukaemia and transformed neural stem cells. In contast,
neuroblastoma cells that lack N-Myc amplification do not require
MondoA for viability; however, overexpression of N-Myc in these
cells drives MondoA dependence. Together, these data suggest that
neuroblastoma cells with high N-Myc expression depend on
MondoA/Mlx for their growth and survival.
There are over 1000 Myc/Max and MondoA/Mlx co-regulated
genes in neuroblastoma cells including many metabolic genes
(Carroll et al, 2015). Multiple MondoA-dependent pathways are
required for N-Myc-driven survival/growth, providing the
mechanistic basis of the dependence of N-Myc-overexpressing
cells on MondoA. For example, MondoA depletion reduces
N-Myc-driven expression of genes involved in glutamine uptake
and utilisation, resulting in reduced global cellular biosynthesis,
reduced mitochondrial metabolic capacity and a subsequent
reduction in oxygen consumption. MondoA loss results in reduced
activity of many nutrient utilisation and biosynthetic pathways.
These findings suggest that MondoA supports the metabolic
changes driven by and required by N-Myc overexpression.
Furthermore, cells driven by N-Myc overepression have an
increased demand for biosynthetic and bioeneregetic substrates
that cannot be met by low MondoA levels. This mismatch
eventually leads to apoptosis and a blockade of tumourigenesis.
The patholgical significance of the cooperation between N-Myc
and MondoA is highlighted by the finding that the highest
expression of a seven-gene signature comprising MondoA and six
metabolic genes correlates with poor clinical outcome in
neuroblastoma and hepatocellular carcinoma. Reflecting the






apparent functional differences in the extended Myc network in
TNBC and neuroblastoma, this same gene signature does not
correlate with clinical outcome in invasive breast carcinoma.
CONCLUSIONS
These three studies highlight the complex interactions between the
members of the extended Myc network in metabolism and
tumourigenesis (Parmenter et al, 2014; Carroll et al, 2015; Shen
et al, 2015). The studies in TNBC and BRAFV600 melanoma
suggest that MondoA and Myc function antagonistically in
controlling glucose uptake/glycolysis. In contrast, in neuroblas-
toma, N-Myc amplification drives a dependence on MondoA and
Mlx (Figure 2). These findings seem contradictory, but we suggest
that the activities of Myc and MondoA function principally to
match the demand for biosynthetic precursors with their
availability. We speculate that in TNBC, TXNIP suppression by
Myc increases the availability of glucose to support Myc-driven
biosynthetic reactions. In contrast, in neuroblastoma, N-Myc
increases MondoA levels that in turn activate glutaminolysis and
lipogenesis to support N-Myc-driven biosynthetic reactions.
Together, these data suggest that in cells or tumours that depend
primarily on glucose catabolism to fuel biosynthesis, Myc and
MondoA will function antagonistically. In contrast, in cells or
tumours that depend primarily on catabolism of glutamine and
lipids to fuel biosynthesis, Myc and MondoA will function
collaboratively.
How broadly the complex interplay between Myc and MondoA
extends across tumourigenesis remains to be explored. Current
data suggest that the primary function of the MondoA/TXNIP axis
is in growth and tumour suppression. For example, TXNIP is
downregulated in many tumour types and is only infrequently
upregulated in tumours (O’Shea and Ayer, 2013). Furthermore,
MondoA is not strongly downregulated in tumours, but several
common oncogenic drivers suppress its transcriptional activity at
the TXNIP promoter. It will be interesting to determine whether
tumours that show suppression of the MondoA/TXNIP axis are
particularly dependent on glucose. MondoA has been proposed to
function as an oncogene in B-cell acute lymphoblastic leukaemia
(Wernicke et al, 2012). The function of c-Myc in B-ALL is not well
studied, but elevated c-Myc levels do associate with increased risk
of persistent disease (Allen et al, 2014). Whether MondoA is
required for B-ALL growth and tumourigenesis or is required to
support other c-Myc-driven B-cell lymphomas such as Burkitt’s
and diffuse large B-cell should be investigated (Slack and
Gascoyne, 2011). As argued above, these Myc-driven tumours
may be particularly dependent on glutamine or lipid catabolic
pathways.
The highlighted studies indicate that Myc/Max complexes have
cell-type differences in their transcriptional targets. For example, in
neuroblastoma, N-Myc/Max increases the expression of MondoA
and TXNIP (Carroll et al, 2015), whereas in TNBC/ c-Myc
represses TXNIP without influencing MondoA levels (Shen et al,
2015). These cell-type differences may reflect differences in the
pallet of co-activators/co-repressors available in a given cell type, or
they may reflect more indirect mechanisms such as c-Myc- or
MondoA-driven changes in cell metabolism. Furthermore, the
relationship between MondoA and Myc may be influenced by the
relative level of Myc amplification and/or the specific Myc
homologue that is deregulated (Murphy et al, 2008). With the
discovery of Max almost 25 years ago and the demonstration that
Myc/Max complexes functioned as transcriptional activators, there
was hope that determining ‘how’ c-Myc functioned in normal and
pathological settings would follow directly from determining
the cohort of Myc/Max transcriptional targets. However, as many
studies now highlight, studying Myc in isolation provides only
partial answer to what is a complex multidimensional puzzle.
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